<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pioglitazone for type 2 diabetes mellitus - Richter, B - 2006 | Cochrane Library</title> <meta property="og:title" content="Pioglitazone for type 2 diabetes mellitus - Richter, B - 2006 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006060.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD006060.pub2" /> <meta name="citation_title" content="Pioglitazone for type 2 diabetes mellitus" /> <meta name="citation_author" content="Bernd Richter" /> <meta name="citation_author_institution" content="Universitaetsklinikum Duesseldorf, Heinrich‐Heine University" /> <meta name="citation_author_email" content="richterb@uni-duesseldorf.de" /> <meta name="citation_author" content="Elizabeth Bandeira‐Echtler" /> <meta name="citation_author_institution" content="Universitaetsklinikum Duesseldorf, Heinrich‐Heine University" /> <meta name="citation_author" content="Karla Bergerhoff" /> <meta name="citation_author_institution" content="Universitaetsklinikum Duesseldorf, Heinrich‐Heine University" /> <meta name="citation_author" content="Christine Clar" /> <meta name="citation_author_institution" content="Cochrane Metabolic and Endocrine Disorders Group" /> <meta name="citation_author" content="Susanne H Ebrahim" /> <meta name="citation_author_institution" content="Institute for Quality and Efficiency in Health Care" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="4" /> <meta name="citation_doi" content="10.1002/14651858.CD006060.pub2" /> <meta name="citation_date" content="2006" /> <meta name="citation_online_date" content="2006/10/18" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006060.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006060.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006060.pub2/pdf/CDSR/CD006060/CD006060.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Diabetes Mellitus, Type 2 [*drug therapy]; Hypoglycemic Agents [*therapeutic use]; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones [*therapeutic use]" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581423095000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581423095000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1559916431000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581717708000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581717784000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="y8F68iId";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006060\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006060\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","ms","ja"],languageCode:"en",accessStatus:"licensed",doi:"10.1002/14651858.CD006060.pub2",title:"Pioglitazone for type 2 diabetes mellitus",firstPublishedDate:"Oct 18, 2006 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581423095000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581423095000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=y8F68iId&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD006060.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD006060.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006060.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD006060.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD006060.pub2/#" data-copyright="Copyright © 2010 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006060.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resultados&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006060.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-sec1-0006"> Authors' conclusions </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-sec1-0001"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-sec1-0002"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-sec1-0003"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-sec1-0004"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-sec1-0005"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/appendices#CD006060-sec1-0011"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/table_n/CD006060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/table_n/CD006060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD006060.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Pioglitazone for type 2 diabetes mellitus</h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD006060-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006060-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Aronoff 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0001"> <div class="citation-journal">Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, et al. <span class="citation-title">Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6‐month randomized placebo‐controlled dose‐response study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2000</span>;<span class="volume">23</span>(11):1605‐11. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11092281" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+hydrochloride+monotherapy+improves+glycemic+control+in+the+treatment+of+patients+with+type+2+diabetes:+A+6%E2%80%90month+randomized+placebo%E2%80%90controlled+dose%E2%80%90response+study+&author=S+Aronoff&author=S+Rosenblatt&author=S+Braithwaite&author=JW+Egan&author=AL+Mathisen&author=RL+Schneider&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0002"> <div class="citation-journal">Miyazaki Y, Matsuda M, DeFronzo RA. <span class="citation-title">Dose‐response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2002</span>;<span class="volume">25</span>:517‐23. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11874940" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dose%E2%80%90response+effect+of+pioglitazone+on+insulin+sensitivity+and+insulin+secretion+in+type+2+diabetes+&author=Y+Miyazaki&author=M+Matsuda&author=RA+DeFronzo&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Charbonnel 2005a {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0003"> <div class="citation-journal">Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. <span class="citation-title">A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: A randomized, double‐blind, parallel‐group comparison trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(4):399‐405. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15787663" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+long%E2%80%90term+comparison+of+pioglitazone+and+gliclazide+in+patients+with+Type+2+diabetes+mellitus:+A+randomized,+double%E2%80%90blind,+parallel%E2%80%90group+comparison+trial+&author=BH+Charbonnel&author=DR+Matthews&author=G+Schernthaner&author=M+Hanefeld&author=P+Brunetti&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0004"> <div class="citation-journal">Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart, et al. <span class="citation-title">Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2005</span>;<span class="volume">28</span>(3):544‐50. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15735185" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+pioglitazone+and+gliclazide+in+sustaining+glycemic+control+over+2+years+in+patients+with+type+2+diabetes+&author=MH+Tan&author=A+Baksi&author=B+Krahulec&author=P+Kubalski&author=A+Stankiewicz&author=+Urquhart&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">Derosa 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0005"> <div class="citation-journal">Derosa G, Cicero AFG, D'Angelo A, Gaddi A, Ragonesi PD, Piccinni MN, Salvadeo S, Ciccarelli L, Pricolo F, Ghelfi M, Ferrari I, Montagna L, Fogari R. <span class="citation-title">Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride</span>. <span class="citation"> Hypertension Research </span><span class="pubYear">2005</span>;<span class="volume">28</span>(11):917‐924. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16555581" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Thiazolidinedione+effects+on+blood+pressure+in+diabetic+patients+with+metabolic+syndrome+treated+with+glimepiride+&author=G+Derosa&author=AFG+Cicero&author=A+D'Angelo&author=A+Gaddi&author=PD+Ragonesi&author=MN+Piccinni&author=S+Salvadeo&author=L+Ciccarelli&author=F+Pricolo&author=M+Ghelfi&author=I+Ferrari&author=L+Montagna&author=R+Fogari&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0006"> <div class="citation-journal">Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. <span class="citation-title">Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve‐month, multicenter, double‐blind, randomized, controlled, parallel‐group trial</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2004</span>;<span class="volume">26</span>(5):744‐54. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15220018" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+effects+of+pioglitazone+and+rosiglitazone+in+patients+with+diabetes+and+metabolic+syndrome+treated+with+glimepiride:+A+twelve%E2%80%90month,+multicenter,+double%E2%80%90blind,+randomized,+controlled,+parallel%E2%80%90group+trial+&author=G+Derosa&author=AFG+Cicero&author=A+Gaddi&author=PD+Ragonesi&author=E+Fogari&author=G+Bertone&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0007"> <div class="citation-journal">Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R. <span class="citation-title">A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2005</span>;<span class="volume">69</span>(1):5‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+comparison+of+the+effects+of+pioglitazone+and+rosiglitazone+combined+with+glimepiride+on+prothrombotic+state+in+type+2+diabetic+patients+with+the+metabolic+syndrome+&author=G+Derosa&author=AFG+Cicero&author=A+Gaddi&author=PD+Ragonesi&author=MN+Piccinni&author=E+Fogari&author=S+Salvadeo&author=L+Ciccarelli&author=R+Fogari&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">Derosa 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0008"> <div class="citation-journal">Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, et al. <span class="citation-title">Metformin‐pioglitazone and metformin‐rosiglitazone effects on non‐conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome</span>. <span class="citation"> Journal of Clinical Pharmacy and Therapeutics </span><span class="pubYear">2006</span>;<span class="volume">31</span>:375‐83. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16882108" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metformin%E2%80%90pioglitazone+and+metformin%E2%80%90rosiglitazone+effects+on+non%E2%80%90conventional+cardiovascular+risk+factors+plasma+level+in+type+2+diabetic+patients+with+metabolic+syndrome+&author=G+Derosa&author=A+D'Angelo&author=PD+Ragonesi&author=L+Ciccarelli&author=MN+Piccinni&author=F+Pricolo&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">Dormandy 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0009"> <div class="citation-journal">Charbonnel B, Dormandy J, Erdmann E, Massi‐Benedetti M, Skene A. <span class="citation-title">The prospective pioglitazone clinical trial in macrovascular events (PROactive'): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(7):1647‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15220241" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+prospective+pioglitazone+clinical+trial+in+macrovascular+events+(PROactive'):+Can+pioglitazone+reduce+cardiovascular+events+in+diabetes?+Study+design+and+baseline+characteristics+of+5,238+patients+&author=B+Charbonnel&author=J+Dormandy&author=E+Erdmann&author=M+Massi‐Benedetti&author=A+Skene&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0010"> <div class="citation-journal">Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi‐Benedetti M, Moules IK, et al. <span class="citation-title">Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2005</span>;<span class="volume">366</span>(9493):1279‐89. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16214598" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Secondary+prevention+of+macrovascular+events+in+patients+with+type+2+diabetes+in+the+PROactive+Study+(PROspective+pioglitAzone+Clinical+Trial+in+macroVascular+Events):+A+randomised+controlled+trial+&author=JA+Dormandy&author=B+Charbonnel&author=DJ+Eckland&author=E+Erdmann&author=M+Massi%E2%80%90Benedetti&author=IK+Moules&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0011"> <div class="citation-journal">Scheen AJ, Lefebvre PJ. <span class="citation-title">Proactive study: Secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients</span>. <span class="citation"> Revue Medicale de Liege </span><span class="pubYear">2005</span>;<span class="volume">60</span>(11):896‐901. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16402538" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Proactive+study:+Secondary+cardiovascular+prevention+with+pioglitazione+in+type+2+diabetic+patients+&author=AJ+Scheen&author=PJ+Lefebvre&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Ebeling 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0012"> <div class="citation-journal">Ebeling P, Teppo A‐M, Koistinen HA, Koivisto VA. <span class="citation-title">Concentration of the complement activation product, acylation‐stimulating protein, is related to C‐reactive protein in patients with type 2 diabetes</span>. <span class="citation"> Metabolism: Clinical &amp; Experimental </span><span class="pubYear">2001</span>;<span class="volume">50</span>(3):283‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Concentration+of+the+complement+activation+product,+acylation%E2%80%90stimulating+protein,+is+related+to+C%E2%80%90reactive+protein+in+patients+with+type+2+diabetes+&author=P+Ebeling&author=A%E2%80%90M+Teppo&author=HA+Koistinen&author=VA+Koivisto&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">Goke 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0013"> <div class="citation-journal">Goke B, German Pioglitazone Study Group. <span class="citation-title">Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus</span>. <span class="citation"> Treatments in Endocrinology </span><span class="pubYear">2002</span>;<span class="volume">1</span>(5):329‐36. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15832486" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improved+glycemic+control+and+lipid+profile+in+a+randomized+study+of+pioglitazone+compared+with+acarbose+in+patients+with+type+2+diabetes+mellitus+&author=B+Goke&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0014"> <div class="citation-journal">Goke B, Lubben G, Bates PC. <span class="citation-title">Coefficient of beta‐Cell Failure in Patients with Type 2 Diabetes Treated with Pioglitazone or Acarbose</span>. <span class="citation"> Experimental &amp; Clinical Endocrinology &amp; Diabetes </span><span class="pubYear">2004</span>;<span class="volume">112</span>(2):115‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Coefficient+of+beta%E2%80%90Cell+Failure+in+Patients+with+Type+2+Diabetes+Treated+with+Pioglitazone+or+Acarbose+&author=B+Goke&author=G+Lubben&author=PC+Bates&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Goldberg 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0015"> <div class="citation-journal">Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ. <span class="citation-title">A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2005</span>;<span class="volume">28</span>(7):1547‐1554. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15983299" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+comparison+of+lipid+and+glycemic+effects+of+pioglitazone+and+rosiglitazone+in+patients+with+type+2+diabetes+and+dyslipidemia+&author=RB+Goldberg&author=DM+Kendall&author=MA+Deeg&author=JB+Buse&author=AJ+Zagar&author=JA+Pinaire&author=MH+Tan&author=MA+Khan&author=AT+Perez&author=SJ+Jacober&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Hanefeld 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0016"> <div class="citation-journal">Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. <span class="citation-title">One‐Year Glycemic Control with A Sulfonylurea Plus Pioglitazone Versus A Sulfonylurea Plus Metformin in Patients with Type 2 Diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(1):141‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14693980" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=One%E2%80%90Year+Glycemic+Control+with+A+Sulfonylurea+Plus+Pioglitazone+Versus+A+Sulfonylurea+Plus+Metformin+in+Patients+with+Type+2+Diabetes+&author=M+Hanefeld&author=P+Brunetti&author=GH+Schernthaner&author=DR+Matthews&author=BH+Charbonnel&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Jovanovic 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0017"> <div class="citation-journal">Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, et al. <span class="citation-title">Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2004</span>;<span class="volume">63</span>(2):127‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+of+type+2+diabetes+with+a+combination+regimen+of+repaglinide+plus+pioglitazone&author=L+Jovanovic&author=DR+Hassman&author=B+Gooch&author=R+Jain&author=S+Greco&author=N+Khutoryansky&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">Langenfeld 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0018"> <div class="citation-journal">Forst T, Hohberg C, Fuellert SD, Lubben G, Konrad T, Lobig M, et al. <span class="citation-title">Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes</span>. <span class="citation"> Hormone &amp; Metabolic Research </span><span class="pubYear">2005</span>;<span class="volume">37</span>(8):521‐527. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacological+PPARgamma+stimulation+in+contrast+to+beta+cell+stimulation+results+in+an+improvement+in+adiponectin+and+proinsulin+intact+levels+and+reduces+intima+media+thickness+in+patients+with+type+2+diabetes+&author=T+Forst&author=C+Hohberg&author=SD+Fuellert&author=G+Lubben&author=T+Konrad&author=M+Lobig&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0019"> <div class="citation-journal">Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, et al. <span class="citation-title">Pioglitazone decreases carotid intima‐media thickness independently of glycemic control in patients with type 2 diabetes mellitus: Results from a controlled randomized study</span>. <span class="citation"> Circulation </span><span class="pubYear">2005</span>;<span class="volume">111</span>(19):2525‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15883215" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+decreases+carotid+intima%E2%80%90media+thickness+independently+of+glycemic+control+in+patients+with+type+2+diabetes+mellitus:+Results+from+a+controlled+randomized+study+&author=MR+Langenfeld&author=T+Forst&author=C+Hohberg&author=P+Kann&author=G+Lubben&author=T+Konrad&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006060-bib-0020"> <div class="citation-journal">Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T. <span class="citation-title">Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study</span>. <span class="citation"> Journal of the American College of Cardiology </span><span class="pubYear">2005</span>;<span class="volume">45</span>(12):1925‐1931. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15963388" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improvement+of+cardiovascular+risk+markers+by+pioglitazone+is+independent+from+glycemic+control:+Results+from+the+pioneer+study+&author=A+Pfutzner&author=N+Marx&author=G+Lubben&author=M+Langenfeld&author=D+Walcher&author=T+Konrad&author=T+Forst&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Lawrence 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0021"> <div class="citation-journal">Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD. <span class="citation-title">Favorable Effects of Pioglitazone and Metformin Compared with Gliclazide on Lipoprotein Subfractions in Overweight Patients with Early Type 2 Diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(1):41‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14693964" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Favorable+Effects+of+Pioglitazone+and+Metformin+Compared+with+Gliclazide+on+Lipoprotein+Subfractions+in+Overweight+Patients+with+Early+Type+2+Diabetes+&author=JM+Lawrence&author=J+Reid&author=GJ+Taylor&author=C+Stirling&author=JPD+Reckless&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Matthews 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0022"> <div class="citation-journal">Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. <span class="citation-title">Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study</span>. <span class="citation"> Diabetes/Metabolism Research Reviews </span><span class="pubYear">2005</span>;<span class="volume">21</span>(2):167‐74. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+therapy+with+addition+of+pioglitazone+to+metformin+compared+with+the+addition+of+gliclazide+to+metformin+in+patients+with+type+2+diabetes:+A+randomized,+comparative+study+&author=DR+Matthews&author=BH+Charbonnel&author=M+Hanefeld&author=P+Brunetti&author=G+Schernthaner&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Mattoo 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0023"> <div class="citation-journal">Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M. <span class="citation-title">Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six‐month, randomized, double‐blind, prospective, multicenter, parallel‐group study</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2005</span>;<span class="volume">27</span>(5):554‐567. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15978304" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+effects+of+pioglitazone+in+combination+with+insulin+in+patients+with+type+2+diabetes+mellitus+whose+disease+is+not+adequately+controlled+with+insulin+therapy:+Results+of+a+six%E2%80%90month,+randomized,+double%E2%80%90blind,+prospective,+multicenter,+parallel%E2%80%90group+study+&author=V+Mattoo&author=D+Eckland&author=M+Widel&author=S+Duran&author=C+Fajardo&author=J+Strand&author=D+Knight&author=L+Grossman&author=D+Oakley&author=M+Tan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">Pavo 2003 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0024"> <div class="citation-journal">Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, et al. <span class="citation-title">Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2003</span>;<span class="volume">88</span>(4):1637‐45. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+compared+with+metformin+on+glycemic+control+and+indicators+of+insulin+sensitivity+in+recently+diagnosed+patients+with+type+2+diabetes+&author=I+Pavo&author=G+Jermendy&author=TT+Varkonyi&author=Z+Kerenyi&author=A+Gyimesi&author=S+Shoustov&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Scherbaum 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0025"> <div class="citation-journal">Scherbaum WA, Goke B. <span class="citation-title">Metabolic efficacy and safety of once‐daily pioglitazone monotherapy in patients with type 2 diabetes: A double‐blind, placebo‐controlled study</span>. <span class="citation"> Hormone &amp; Metabolic Research </span><span class="pubYear">2002</span>;<span class="volume">34</span>(10):589‐95. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+efficacy+and+safety+of+once%E2%80%90daily+pioglitazone+monotherapy+in+patients+with+type+2+diabetes:+A+double%E2%80%90blind,+placebo%E2%80%90controlled+study+&author=WA+Scherbaum&author=B+Goke&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Schernthaner 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0026"> <div class="citation-journal">Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. <span class="citation-title">Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomized trial</span>. <span class="citation"> Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2004</span>;<span class="volume">89</span>(12):6068‐76. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+pioglitazone+versus+metformin+in+patients+with+type+2+diabetes+mellitus:+A+double%E2%80%90blind,+randomized+trial+&author=G+Schernthaner&author=DR+Matthews&author=B+Charbonnel&author=M+Hanefeld&author=P+Brunetti&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Smith 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0027"> <div class="citation-journal">Smith SR, Jonge L, Volaufova J, Li Y, Xie H, Bray GA. <span class="citation-title">Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial</span>. <span class="citation"> Metabolism: Clinical &amp; Experimental </span><span class="pubYear">2005</span>;<span class="volume">54</span>(1):24‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+body+composition+and+energy+expenditure:+A+randomized+controlled+trial+&author=SR+Smith&author=L+Jonge&author=J+Volaufova&author=Y+Li&author=H+Xie&author=GA+Bray&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Tan 2004a {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0028"> <div class="citation-journal">Tan M, Johns D, Galvez GG, Antunez O, Fabian G, Flores‐Lozano F, et al. <span class="citation-title">Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, parallel‐group trial</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2004</span>;<span class="volume">26</span>(5):680‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15220012" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+and+glimepiride+on+glycemic+control+and+insulin+sensitivity+in+Mexican+patients+with+type+2+diabetes+mellitus:+A+multicenter,+randomized,+double%E2%80%90blind,+parallel%E2%80%90group+trial+&author=M+Tan&author=D+Johns&author=GG+Galvez&author=O+Antunez&author=G+Fabian&author=F+Flores%E2%80%90Lozano&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">Tan 2004b {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0029"> <div class="citation-journal">Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW et al ‐ GLAC Study Group. <span class="citation-title">Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2004</span>;<span class="volume">21</span>(8):859‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15270789" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sustained+effects+of+pioglitazone+vs.+glibenclamide+on+insulin+sensitivity,+glycaemic+control,+and+lipid+profiles+in+patients+with+Type+2+diabetes+&author=MH+Tan&author=D+Johns&author=J+Strand&author=J+Halse&author=S+Madsbad&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Watanabe 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0030"> <div class="citation-journal">Watanabe I, Tani S, Anazawa T, Kushiro T, Kanmatsuse K. <span class="citation-title">Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2005</span>;<span class="volume">68</span>(2):104‐10. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+arteriosclerosis+in+comparison+with+that+of+glibenclamide&author=I+Watanabe&author=S+Tani&author=T+Anazawa&author=T+Kushiro&author=K+Kanmatsuse&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006060-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Yamanouchi 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0031"> <div class="citation-journal">Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. <span class="citation-title">Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(8):980‐985. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16026361" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+metabolic+effects+of+pioglitazone,+metformin,+and+glimepiride+over+1+year+in+Japanese+patients+with+newly+diagnosed+Type+2+diabetes+&author=T+Yamanouchi&author=T+Sakai&author=K+Igarashi&author=K+Ichiyanagi&author=H+Watanabe&author=T+Kawasaki&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006060-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006060-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Koshiyama 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0032"> <div class="citation-journal">Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. <span class="citation-title">Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes</span>. <span class="citation"> The Journal of Clinical Endocrinology &amp; Metabolism </span><span class="pubYear">2001</span>;<span class="volume">86</span>:3452‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Inhibitory+effect+of+pioglitazone+on+carotid+arterial+wall+thickness+in+type+2+diabetes&author=H+Koshiyama&author=D+Shimono&author=N+Kuwamura&author=J+Minamikawa&author=Y+Nakamura&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Nagashima 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0033"> <div class="citation-journal">Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart‐Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. <span class="citation-title">Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus</span>. <span class="citation"> Journal of Clinical Investigation </span><span class="pubYear">2005</span>;<span class="volume">115</span>(5):1323‐1332. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15841215" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+the+PPARgamma+agonist+pioglitazone+on+lipoprotein+metabolism+in+patients+with+type+2+diabetes+mellitus+&author=K+Nagashima&author=C+Lopez&author=D+Donovan&author=C+Ngai&author=N+Fontanez&author=A+Bensadoun&author=J+Fruchart%E2%80%90Najib&author=S+Holleran&author=JS+Cohn&author=R+Ramakrishnan&author=HN+Ginsberg&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Nishio 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0034"> <div class="citation-journal">Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T. <span class="citation-title">A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2006</span>;<span class="volume">29</span>(1):101‐106. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16373904" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized+comparison+of+pioglitazone+to+inhibit+restenosis+after+coronary+stenting+in+patients+with+type+2+diabetes+&author=K+Nishio&author=M+Sakurai&author=T+Kusuyama&author=M+Shigemitsu&author=T+Fukui&author=K+Kawamura&author=S+Itoh&author=N+Konno&author=T+Katagiri&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Roberts 2005b {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0035"> <div class="citation-journal">Roberts VL, Stewart J, Issa M, Lake B, Melis R. <span class="citation-title">Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30‐week, randomized, double‐blind, placebo‐controlled, parallel‐group study</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2005</span>;<span class="volume">27</span>(10):1535‐47. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16330290" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Triple+therapy+with+glimepiride+in+patients+with+type+2+diabetes+mellitus+inadequately+controlled+by+metformin+and+a+thiazolidinedione:+Results+of+a+30%E2%80%90week,+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled,+parallel%E2%80%90group+study+&author=VL+Roberts&author=J+Stewart&author=M+Issa&author=B+Lake&author=R+Melis&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Schofl 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0036"> <div class="citation-journal">Schofl C, Luebben G. <span class="citation-title">Pioglitazone improves diabetic dyslipidaemia in patients with type 2 diabetes mellitus with or without lipid‐lowering therapy</span>. <span class="citation"> Clinical Drug Investigation </span><span class="pubYear">2005</span>;<span class="volume">25</span>(5):341‐345. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17532672" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+improves+diabetic+dyslipidaemia+in+patients+with+type+2+diabetes+mellitus+with+or+without+lipid%E2%80%90lowering+therapy+&author=C+Schofl&author=G+Luebben&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Takagi 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0037"> <div class="citation-journal">Takagi T, Yamamuro A, Tamita K, Katayama M, Morioka S. <span class="citation-title">Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: An intravascular ultrasound study</span>. <span class="citation"> Journal of Cardiology </span><span class="pubYear">2005</span>;<span class="volume">45</span>(4):139‐147. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15875535" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Thiazolidinedione+treatment+attenuates+diffuse+neointimal+hyperplasia+in+restenotic+lesions+after+coronary+stent+implantation+in+type+2+diabetic+patients:+An+intravascular+ultrasound+study+&author=T+Takagi&author=A+Yamamuro&author=K+Tamita&author=M+Katayama&author=S+Morioka&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006060-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">Tseng 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0038"> <div class="citation-journal">Tseng CH, Huang TS. <span class="citation-title">Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients</span>. <span class="citation"> Diabetes Research &amp; Clinical Practice </span><span class="pubYear">2005</span>;<span class="volume">70</span>(2):193‐194. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+with+sulfonylurea:+glycemic+and+lipid+effects+in+Taiwanese+type+2+diabetic+patients+&author=CH+Tseng&author=TS+Huang&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006060-bbs1-0003"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006060-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006060-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">ACCORD {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0039"> <div class="citation-other"><span class="citation-title">Action to Control Cardiovascular Risk in Diabetes (ACCORD)</span>. Ongoing study Recruitment occurred in two non‐contiguous periods: an initial period that began in January 2001 for the Vanguard Phase of the trial (during which 1174 participants were randomized) and then a subsequent period beginning in January 2003 and ending in October 2005.Follow‐up is scheduled to end in June 2009, with the primary results announced in early 2010.. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006060-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">BARI‐2D {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0040"> <div class="citation-other"><span class="citation-title">Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)</span>. Ongoing study Study start: September 2000; <br></br> Study completion: June 2007. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006060-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">CHICAGO {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0041"> <div class="citation-other"><span class="citation-title">A Study of Pioglitazone HCl Versus Glimepiride in Subjects With Type 2 Diabetes Measuring the Progression of Atherosclerosis (CHICAGO)</span>. Ongoing study Study start: August 2003; <br></br> Study completion: October 2006 <br></br> Last follow‐up: April 2006; <br></br> Data entry closure: July 2006. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006060-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">PERISCOPE {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0042"> <div class="citation-other"><span class="citation-title">Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE)</span>. Ongoing study Study start: August 2003; <br></br> Expected completion: March 2008 <br></br> Last follow‐up: August 2007; <br></br> Data entry closure: November 2007. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006060-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">PPAR {published data only} </h4> </div> <div class="bibliography-section" id="CD006060-bib-0043"> <div class="citation-other"><span class="citation-title">Pioglitazone Protects DM Patients Against Re‐Infarction (PPAR Study)</span>. Ongoing study Study start: April 2005; Expected completion: April 2009 <br></br> Last follow‐up: April 2009; <br></br> Data entry closure: April 2009. <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006060-bbs1-0004"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006060-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006060-bbs1-0003">ongoing studies</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">ADA 1997</h4> </div> <div class="bibliography-section" id="CD006060-bib-0044"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1997</span>;<span class="volume">20 Suppl 1</span>:S5‐20. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">ADA 1999</h4> </div> <div class="bibliography-section" id="CD006060-bib-0045"> <div class="citation-journal">The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. <span class="citation-title">Report of the Expert Committee on the diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1999</span>;<span class="volume">22 Suppl 1</span>:S5‐19. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Armour 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0046"> <div class="citation-journal">Armour T, Norris S, Brown D, Zhang X, Caspersen C. <span class="citation-title">Initiating and maintaining physical activity for type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2004</span>, Issue 1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Initiating+and+maintaining+physical+activity+for+type+2+diabetes+mellitus&author=T+Armour&author=S+Norris&author=D+Brown&author=X+Zhang&author=C+Caspersen&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Baba 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0047"> <div class="citation-journal">Baba S. <span class="citation-title">Pioglitazone: A review of Japanese clinical studies</span>. <span class="citation"> Current Medical Research &amp; Opinion </span><span class="pubYear">2001</span>;<span class="volume">17</span>(3):166‐89. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone:+A+review+of+Japanese+clinical+studies&author=S+Baba&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Belcher 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0048"> <div class="citation-journal">Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. <span class="citation-title">Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2004</span>;<span class="volume">58</span>(9):833‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15529516" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+effects+of+treatment+of+type+2+diabetes+with+pioglitazone,+metformin+and+gliclazide+&author=G+Belcher&author=C+Lambert&author=KL+Goh&author=G+Edwards&author=M+Valbuena&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">Belcher 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0049"> <div class="citation-journal">Belcher G, Schernthaner G. <span class="citation-title">Changes in liver tests during 1‐year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(8):973‐979. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16026360" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Changes+in+liver+tests+during+1%E2%80%90year+treatment+of+patients+with+Type+2+diabetes+with+pioglitazone,+metformin+or+gliclazide+&author=G+Belcher&author=G+Schernthaner&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">Betteridge 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0050"> <div class="citation-journal">Betteridge DJ, Verges B. <span class="citation-title">Long‐term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>(12):2477‐2481. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16283239" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+effects+on+lipids+and+lipoproteins+of+pioglitazone+versus+gliclazide+addition+to+metformin+and+pioglitazone+versus+metformin+addition+to+sulphonylurea+in+the+treatment+of+type+2+diabetes+&author=DJ+Betteridge&author=B+Verges&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">Black 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0051"> <div class="citation-journal">Black C, McIntyre L, Mesa‐Perez JA, Royle PL, Thomas S, Waugh N. <span class="citation-title">Meglitinide analogues for type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2003</span>, Issue 4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meglitinide+analogues+for+type+2+diabetes+mellitus&author=C+Black&author=L+McIntyre&author=JA+Mesa%E2%80%90Perez&author=PL+Royle&author=S+Thomas&author=N+Waugh&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">Bloomgarden 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0052"> <div class="citation-journal">Bloomgarden ZT. <span class="citation-title">Thiazolidinediones</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2005</span>;<span class="volume">28</span>(2):488‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15677823" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Thiazolidinediones&author=ZT+Bloomgarden&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">Boucher 2002</h4> </div> <div class="bibliography-section" id="CD006060-bib-0053"> <div class="citation-other">Boucher M, McAuley L, Brown A, Keely E, Skidmore B. <span class="citation-title">Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti‐diabetic agents</span>. Ottawa, Canada. Canadian Coordinating Office for Health Technology Assessment, 2002. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">Boucher 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0054"> <div class="citation-book">Boucher M, McAuley L, Brown A, Keely E, Skidmore B. <span class="citation">Efficacy of rosiglitazone and pioglitazone compared to other anti‐diabetic agents: systematic review and budget impact analysis</span>. Ottawa, Canada: Canadian Office for Health Technology Assessment, <span class="pubYear">2003</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">Burt 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0055"> <div class="citation-journal">Burt AL, Green S, Kwan I, Mugglestone M, Thomas J. <span class="citation-title">Intranasal insulin for type 1 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intranasal+insulin+for+type+1+diabetes+mellitus&author=AL+Burt&author=S+Green&author=I+Kwan&author=M+Mugglestone&author=J+Thomas&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">Campbell 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0056"> <div class="citation-journal">Campbell IW. <span class="citation-title">Long‐term glycaemic control with pioglitazone in patients with type 2 diabetes</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2004</span>;<span class="volume">58</span>(2):192‐200. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15055868" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+glycaemic+control+with+pioglitazone+in+patients+with+type+2+diabetes&author=IW+Campbell&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Ceriello 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0057"> <div class="citation-journal">Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. <span class="citation-title">Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2005</span>;<span class="volume">28</span>(2):266‐272. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15677777" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+effect+of+pioglitazone+with+metformin+or+sulfonylurea+(monotherapy+and+combination+therapy)+on+postload+glycemia+and+composite+insulin+sensitivity+index+during+an+oral+glucose+tolerance+test+in+patients+with+type+2+diabetes+&author=A+Ceriello&author=D+Johns&author=M+Widel&author=DJ+Eckland&author=KJ+Gilmore&author=MH+Tan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Charbonnel 2005b</h4> </div> <div class="bibliography-section" id="CD006060-bib-0058"> <div class="citation-journal">Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M, et al. <span class="citation-title">Pioglitazone elicits long‐term improvements in insulin sensitivity in patients with type 2 diabetes: Comparisons with gliclazide‐based regimens</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>(3):553‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15739120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+elicits+long%E2%80%90term+improvements+in+insulin+sensitivity+in+patients+with+type+2+diabetes:+Comparisons+with+gliclazide%E2%80%90based+regimens+&author=B+Charbonnel&author=M+Roden&author=R+Urquhart&author=S+Mariz&author=D+Johns&author=M+Mihm&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Charbonnel 2005c</h4> </div> <div class="bibliography-section" id="CD006060-bib-0059"> <div class="citation-journal">Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. <span class="citation-title">Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>:1093‐104. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15889234" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+efficacy+and+tolerability+of+add%E2%80%90on+pioglitazone+therapy+to+failing+monotherapy+compared+with+addition+of+gliclazide+or+metformin+in+patients+with+type+2+diabetes+&author=B+Charbonnel&author=G+Schernthaner&author=P+Brunetti&author=DR+Matthews&author=R+Urquhart&author=MH+Tan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Chilcott 2001a</h4> </div> <div class="bibliography-section" id="CD006060-bib-0060"> <div class="citation-other">Chilcott J, Wight J, Jones ML, Tappenden P. <span class="citation-title">The clinical effectiveness and cost‐effectiveness of pioglitazone for type 2 diabetes mellitus: A rapid and systematic review</span>. Winchester, England. Health Technology Assessment, 2001. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Chilcott 2001b</h4> </div> <div class="bibliography-section" id="CD006060-bib-0061"> <div class="citation-journal">Chilcott J, Tappenden P, Jones ML, Wight JP. <span class="citation-title">A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2001</span>;<span class="volume">23</span>(11):1792‐823. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11768834" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+systematic+review+of+the+clinical+effectiveness+of+pioglitazone+in+the+treatment+of+type+2+diabetes+mellitus+&author=J+Chilcott&author=P+Tappenden&author=ML+Jones&author=JP+Wight&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Chiquette 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0062"> <div class="citation-journal">Chiquette E, Ramirez G, DeFronzo R. <span class="citation-title">A meta‐analysis comparing the effect of thiazolidinediones on cardiovascular risk factors</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">2004</span>;<span class="volume">164</span>(19):2097‐104. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15505122" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+meta%E2%80%90analysis+comparing+the+effect+of+thiazolidinediones+on+cardiovascular+risk+factors+&author=E+Chiquette&author=G+Ramirez&author=R+DeFronzo&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Cohen 1960</h4> </div> <div class="bibliography-section" id="CD006060-bib-0063"> <div class="citation-journal">Cohen J. <span class="citation-title">A coefficient of agreement for nominal scales</span>. <span class="citation"> Educational and Psychological Measurement </span><span class="pubYear">1960</span>;<span class="volume">20</span>:37‐46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+coefficient+of+agreement+for+nominal+scales&author=J+Cohen&publication_year=1960&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">Czoski‐Murray 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0064"> <div class="citation-other">Czoski‐Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. <span class="citation-title">Clinical effectiveness and cost‐effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: A systematic review and economic evaluation</span>. Winchester, England. Health Technology Assessment, 2004. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">DCCT 1993</h4> </div> <div class="bibliography-section" id="CD006060-bib-0065"> <div class="citation-journal">The Diabetes Control and Complications Trial Research Group. <span class="citation-title">The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">1993</span>;<span class="volume">329</span>(14):977‐86. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8366922" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">DeFronzo 1992</h4> </div> <div class="bibliography-section" id="CD006060-bib-0066"> <div class="citation-journal">DeFronzo RA, Bonadonna RC, Ferrannini E. <span class="citation-title">Pathogenesis of NIDDM: a balanced overview</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1992</span>;<span class="volume">15</span>:318‐68. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1532777" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pathogenesis+of+NIDDM:+a+balanced+overview&author=RA+DeFronzo&author=RC+Bonadonna&author=E+Ferrannini&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">Einhorn 2000</h4> </div> <div class="bibliography-section" id="CD006060-bib-0067"> <div class="citation-journal">Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. <span class="citation-title">Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo‐controlled study</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2000</span>;<span class="volume">22</span>(12):1395‐1409. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11192132" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+hydrochloride+in+combination+with+metformin+in+the+treatment+of+type+2+diabetes+mellitus:+A+randomized,+placebo%E2%80%90controlled+study+&author=D+Einhorn&author=M+Rendell&author=J+Rosenzweig&author=JW+Egan&author=AL+Mathisen&author=RL+Schneider&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">Ewart 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0068"> <div class="citation-journal">Ewart RM. <span class="citation-title">The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study</span>. <span class="citation"> BMJ </span><span class="pubYear">2001</span>;<span class="volume">323</span>(7317):854‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11597972" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+case+against+aggressive+treatment+of+type+2+diabetes:+critique+of+the+UK+prospective+diabetes+study+&author=RM+Ewart&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">Farley‐Hills 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0069"> <div class="citation-journal">Farley‐Hills E, Sivasankar R, Martin M. <span class="citation-title">Fatal liver failure associated with pioglitazone</span>. <span class="citation"> BMJ </span><span class="pubYear">2004</span>;<span class="volume">329</span>(7463):429. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15321899" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fatal+liver+failure+associated+with+pioglitazone&author=E+Farley%E2%80%90Hills&author=R+Sivasankar&author=M+Martin&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Freemantle 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0070"> <div class="citation-journal">Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. <span class="citation-title">Composite outcomes in randomized trials: greater precision but with greater uncertainty?</span>. <span class="citation"> JAMA </span><span class="pubYear">2003</span>;<span class="volume">289</span>(19):2554‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12759327" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Composite+outcomes+in+randomized+trials:+greater+precision+but+with+greater+uncertainty?&author=N+Freemantle&author=M+Calvert&author=J+Wood&author=J+Eastaugh&author=C+Griffin&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">Gillies 2000</h4> </div> <div class="bibliography-section" id="CD006060-bib-0071"> <div class="citation-journal">Gillies PS, Dunn CJ. <span class="citation-title">Pioglitazone</span>. <span class="citation"> Drugs </span><span class="pubYear">2000</span>;<span class="volume">60</span>(2):333‐43. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10983737" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone&author=PS+Gillies&author=CJ+Dunn&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">Gimenez‐Perez 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0072"> <div class="citation-journal">Gimenez‐Perez G, Gonzalez‐Clemente JM, Mauricio D. <span class="citation-title">Lifestyle interventions for preventing type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2001</span>, Issue 1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lifestyle+interventions+for+preventing+type+2+diabetes+mellitus&author=G+Gimenez%E2%80%90Perez&author=JM+Gonzalez%E2%80%90Clemente&author=D+Mauricio&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Haffner 1998</h4> </div> <div class="bibliography-section" id="CD006060-bib-0073"> <div class="citation-journal">Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. <span class="citation-title">Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">1998</span>;<span class="volume">339</span>:229‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9673301" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mortality+from+coronary+heart+disease+in+subjects+with+type+2+diabetes+and+in+nondiabetic+subjects+with+and+without+prior+myocardial+infarction+&author=SM+Haffner&author=S+Lehto&author=T+Ronnemaa&author=K+Pyorala&author=M+Laakso&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Hanefeld 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0074"> <div class="citation-journal">Hanefeld M, Belcher G. <span class="citation-title">Safety profile of pioglitazone</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2001</span>;<span class="volume">Suppl 121</span>:27‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+profile+of+pioglitazone&author=M+Hanefeld&author=G+Belcher&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Hanefeld 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0075"> <div class="citation-journal">Hanefeld M. <span class="citation-title">Outcome studies in type 2 diabetes</span>. <span class="citation"> Current Medical Research &amp; Opinion, Supplement </span><span class="pubYear">2005</span>;<span class="volume">21</span>(1):S41‐S48. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Outcome+studies+in+type+2+diabetes&author=M+Hanefeld&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">HDS 1993</h4> </div> <div class="bibliography-section" id="CD006060-bib-0076"> <div class="citation-journal">The Hypertension in Diabetes Study Group. <span class="citation-title">Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">1993</span>;<span class="volume">11</span>:309‐17. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8387089" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">Higgins 2002</h4> </div> <div class="bibliography-section" id="CD006060-bib-0077"> <div class="citation-journal">Higgins JPT, Thompson SG. <span class="citation-title">Quantifying heterogeneity in a meta‐analysis</span>. <span class="citation"> Statistics in medicine </span><span class="pubYear">2002</span>;<span class="volume">21</span>:1539‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12111919" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quantifying+heterogeneity+in+a+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Higgins 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0078"> <div class="citation-journal">Higgins JPT, Thompson SG, Deeks JJ, Altman DG. <span class="citation-title">Measuring inconsistency in meta‐analysis</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">327</span>:557‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12958120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Measuring+inconsistency+in+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">Higgins 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0079"> <div class="citation-other">Higgins JPT, Green S, editors. <span class="citation-title">Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</span>. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Hisamochi 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0080"> <div class="citation-journal">Hisamochi A, Kumashiro R, Koga Y, Tanaka E, Ide T, Hino T. <span class="citation-title">A case of drug induced liver injury related pioglitazone</span>. <span class="citation"> Nippon Shokakibyo Gakkai Zasshi </span><span class="pubYear">2003</span>;<span class="volume">100</span>(3):333‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12696176" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+case+of+drug+induced+liver+injury+related+pioglitazone&author=A+Hisamochi&author=R+Kumashiro&author=Y+Koga&author=E+Tanaka&author=T+Ide&author=T+Hino&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Kahn 1997</h4> </div> <div class="bibliography-section" id="CD006060-bib-0081"> <div class="citation-book">Kahn SE, Porte D. <span class="citation-title">The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment</span>. In: Porte D, Sherwin RS editor(s). <span class="citation">Ellenberg &amp; Rifkin's Diabetes Mellitus</span>. 5th Edition. Stamford, Conneticut (U.S.A.): Appleton &amp; Lange, <span class="pubYear">1997</span>. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+pathophysiology+of+type+II+(noninsulindependent)+diabetes+mellitus:+implications+for+treatment+&author=SE+Kahn&author=D+Porte&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Khan 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0082"> <div class="citation-journal">Khan M, Xu Y, Edwards G, Urquhart R, Mariz S. <span class="citation-title">Effects of pioglitazone on the components of diabetic dyslipidaemia: Results of double‐blind, multicenter, randomised studies</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2004</span>;<span class="volume">58</span>(10):907‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15587767" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+on+the+components+of+diabetic+dyslipidaemia:+Results+of+double%E2%80%90blind,+multicenter,+randomised+studies+&author=M+Khan&author=Y+Xu&author=G+Edwards&author=R+Urquhart&author=S+Mariz&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">Kipnes 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0083"> <div class="citation-journal">Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. <span class="citation-title">Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo‐controlled study</span>. <span class="citation"> American Journal of Medicine </span><span class="pubYear">2001</span>;<span class="volume">111</span>(1):10‐17. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11448655" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+hydrochloride+in+combination+with+sulfonylurea+therapy+improves+glycemic+control+in+patients+with+type+2+diabetes+mellitus:+A+randomized,+placebo%E2%80%90controlled+study+&author=MS+Kipnes&author=A+Krosnick&author=MS+Rendell&author=JW+Egan&author=AL+Mathisen&author=RL+Schneider&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">Laakso 1999</h4> </div> <div class="bibliography-section" id="CD006060-bib-0084"> <div class="citation-journal">Laakso M. <span class="citation-title">Hyperglycemia and cardiovascular disease in type 2 diabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">1999</span>;<span class="volume">48</span>:937‐42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10331395" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hyperglycemia+and+cardiovascular+disease+in+type+2+diabetes&author=M+Laakso&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">Lenton 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0085"> <div class="citation-journal">Lenton S, Schernthaner G, Edwards G, Lee C, Tan M, Herz M. <span class="citation-title">The efficacy of pioglitazone compared to metformin in drug naive patients with Type 2 diabetes (abstract)</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2003</span>;<span class="volume">Suppl. 2</span>:A287. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+efficacy+of+pioglitazone+compared+to+metformin+in+drug+naive+patients+with+Type+2+diabetes+(abstract)+&author=S+Lenton&author=G+Schernthaner&author=G+Edwards&author=C+Lee&author=M+Tan&author=M+Herz&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">Lester 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0086"> <div class="citation-journal">Lester JW, Fernandes AW. <span class="citation-title">Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2005</span>;<span class="volume">59</span>(2):134‐42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15854187" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+in+a+subgroup+of+patients+with+type+2+diabetes+meeting+the+criteria+for+metabolic+syndrome+&author=JW+Lester&author=AW+Fernandes&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Lindberg 2002</h4> </div> <div class="bibliography-section" id="CD006060-bib-0087"> <div class="citation-journal">Lindberg G, Lindblad U, Melander A. <span class="citation-title">Sulfonylureas for treating type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2002</span>, Issue 4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sulfonylureas+for+treating+type+2+diabetes+mellitus&author=G+Lindberg&author=U+Lindblad&author=A+Melander&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Manson 1991</h4> </div> <div class="bibliography-section" id="CD006060-bib-0088"> <div class="citation-journal">Manson JE, Coldlitz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, et al. <span class="citation-title">A prospective study of maturity‐onset diabetes mellitus and risk of coronary heart disease and stroke in women</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">1991</span>;<span class="volume">151</span>:1141‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2043016" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+prospective+study+of+maturity%E2%80%90onset+diabetes+mellitus+and+risk+of+coronary+heart+disease+and+stroke+in+women+&author=JE+Manson&author=GA+Coldlitz&author=MJ+Stampfer&author=WC+Willett&author=AS+Krolewski&author=B+Rosner&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">May 2002</h4> </div> <div class="bibliography-section" id="CD006060-bib-0089"> <div class="citation-journal">May LD, Lefkowitch JH, Kram MT, Rubin DE. <span class="citation-title">Mixed hepatocellular‐cholestatic liver injury after pioglitazone therapy</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">2002</span>;<span class="volume">136</span>(6):449‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11900497" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mixed+hepatocellular%E2%80%90cholestatic+liver+injury+after+pioglitazone+therapy&author=LD+May&author=JH+Lefkowitch&author=MT+Kram&author=DE+Rubin&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">McAlister 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0090"> <div class="citation-journal">McAlister FA, Straus SE, Sackett DL, Altman DG. <span class="citation-title">Analysis and reporting of factorial trials: a systematic review</span>. <span class="citation"> JAMA </span><span class="pubYear">2003</span>;<span class="volume">289</span>(19):2545‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12759326" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Analysis+and+reporting+of+factorial+trials:+a+systematic+review&author=FA+McAlister&author=SE+Straus&author=DL+Sackett&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">McCormack 2000</h4> </div> <div class="bibliography-section" id="CD006060-bib-0091"> <div class="citation-journal">McCormack J, Greenhalgh T. <span class="citation-title">Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study</span>. <span class="citation"> BMJ </span><span class="pubYear">2000</span>;<span class="volume">320</span>(7251):1720‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10864554" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Seeing+what+you+want+to+see+in+randomised+controlled+trials:+versions+and+perversions+of+UKPDS+data.+United+Kingdom+prospective+diabetes+study+&author=J+McCormack&author=T+Greenhalgh&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Meriden 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0092"> <div class="citation-journal">Meriden T. <span class="citation-title">Progress with thiazolidinediones in the management of type 2 diabetes mellitus</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2004</span>;<span class="volume">26</span>(2):177‐90. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15038941" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Progress+with+thiazolidinediones+in+the+management+of+type+2+diabetes+mellitus&author=T+Meriden&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Misso 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0093"> <div class="citation-journal">Misso ML, O'Connor DA, Egberts KJ, Shaw J. <span class="citation-title">Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Continuous+subcutaneous+insulin+infusion+(CSII)+versus+multiple+insulin+injections+for+type+1+diabetes+mellitus+&author=ML+Misso&author=DA+O'Connor&author=KJ+Egberts&author=J+Shaw&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Moher 1999</h4> </div> <div class="bibliography-section" id="CD006060-bib-0094"> <div class="citation-journal">Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. <span class="citation-title">Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta‐analyses</span>. <span class="citation"> Lancet </span><span class="pubYear">1999</span>;<span class="volume">354</span>(9193):1896‐900. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10584742" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improving+the+quality+of+reports+of+meta%E2%80%90analyses+of+randomised+controlled+trials:+the+QUOROM+statement.+Quality+of+Reporting+of+Meta%E2%80%90analyses+&author=D+Moher&author=DJ+Cook&author=S+Eastwood&author=I+Olkin&author=D+Rennie&author=DF+Stroup&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Montgomery 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0095"> <div class="citation-journal">Montgomery AA, Peters TJ, Little P. <span class="citation-title">Design, analysis and presentation of factorial randomised controlled trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">3</span>:26. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Design,+analysis+and+presentation+of+factorial+randomised+controlled+trials&author=AA+Montgomery&author=TJ+Peters&author=P+Little&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Moore 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0096"> <div class="citation-journal">Moore H, Summerbell C, Hooper, L, Ashton V, Kopelman P. <span class="citation-title">Dietary advice for the prevention of type 2 diabetes mellitus in adults</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dietary+advice+for+the+prevention+of+type+2+diabetes+mellitus+in+adults&author=H+Moore&author=C+Summerbell&author=+Hooper&author=+L&author=V+Ashton&author=P+Kopelman&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Natali 2006</h4> </div> <div class="bibliography-section" id="CD006060-bib-0097"> <div class="citation-journal">Natali A, Ferrannini E. <span class="citation-title">Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2006</span>;<span class="volume">49</span>(3):434‐441. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16477438" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+metformin+and+thiazolidinediones+on+suppression+of+hepatic+glucose+production+and+stimulation+of+glucose+uptake+in+type+2+diabetes:+A+systematic+review+&author=A+Natali&author=E+Ferrannini&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Nathan 1998</h4> </div> <div class="bibliography-section" id="CD006060-bib-0098"> <div class="citation-journal">Nathan DM. <span class="citation-title">Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):832‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742972" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Some+answers,+more+controversy,+from+UKPDS.+United+Kingdom+Prospective+Diabetes+Study&author=DM+Nathan&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">NICE 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0099"> <div class="citation-other"><span class="citation-title">Guidance on the use of pioglitazone for type 2 diabetes mellitus</span>. London. National Institute for Clinical Excellence, 2001. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">NICE 2003a</h4> </div> <div class="bibliography-section" id="CD006060-bib-0100"> <div class="citation-other"><span class="citation-title">Guidance on the use of glitazones for the treatment of type 2 diabetes</span>. London. National Institute for Clinical Excellence, 2003. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">NICE 2003b</h4> </div> <div class="bibliography-section" id="CD006060-bib-0101"> <div class="citation-other"><span class="citation-title">Review of rosiglitazone and pioglitazone for type II diabetes ‐ appraisal (project)</span>. London, UK. National Institute for Clinical Excellence, 2003. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">Ohkubo 1995</h4> </div> <div class="bibliography-section" id="CD006060-bib-0102"> <div class="citation-journal">Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. <span class="citation-title">Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent mellitus: a randomized prospective 6‐year study</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">1995</span>;<span class="volume">28</span>:103‐17. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7587918" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+insulin+therapy+prevents+the+progression+of+diabetic+microvascular+complications+in+Japanese+patients+with+non%E2%80%90insulin%E2%80%90dependent+mellitus:+a+randomized+prospective+6%E2%80%90year+study+&author=Y+Ohkubo&author=H+Kishikawa&author=E+Araki&author=T+Miyata&author=S+Isami&author=S+Motoyoshi&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">Perez 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0103"> <div class="citation-journal">Perez A, Khan M, Johnson T, Karunaratne M. <span class="citation-title">Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2004</span>;<span class="volume">1</span>(1):44‐50. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16305056" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+plus+a+sulphonylurea+or+metformin+is+associated+with+increased+lipoprotein+particle+size+in+patients+with+type+2+diabetes+&author=A+Perez&author=M+Khan&author=T+Johnson&author=M+Karunaratne&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Pinto 2002</h4> </div> <div class="bibliography-section" id="CD006060-bib-0104"> <div class="citation-journal">Pinto AG, Cummings OW, Chalasani N. <span class="citation-title">Severe but reversible cholestatic liver injury after pioglitazone therapy</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">2002</span>;<span class="volume">137</span>(10):857. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12435231" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Severe+but+reversible+cholestatic+liver+injury+after+pioglitazone+therapy&author=AG+Pinto&author=OW+Cummings&author=N+Chalasani&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">PROactive 2006</h4> </div> <div class="bibliography-section" id="CD006060-bib-0105"> <div class="citation-journal">PROactive Study Executive Committee and Data and Safety Monitoring Committee. <span class="citation-title">PROactive study</span>. <span class="citation"> Lancet </span><span class="pubYear">2006</span>;<span class="volume">367</span>(9515):982. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Qayyum 2006</h4> </div> <div class="bibliography-section" id="CD006060-bib-0106"> <div class="citation-journal">Qayyum R, Adomaityte J. <span class="citation-title">Meta‐analysis of the effect of thiazolidinediones on serum C‐reactive protein levels</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2006</span>;<span class="volume">97</span>(5):655‐658. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16490432" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meta%E2%80%90analysis+of+the+effect+of+thiazolidinediones+on+serum+C%E2%80%90reactive+protein+levels&author=R+Qayyum&author=J+Adomaityte&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Rajagopalan 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0107"> <div class="citation-journal">Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT. <span class="citation-title">Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus</span>. <span class="citation"> Drugs &amp; Aging </span><span class="pubYear">2004</span>;<span class="volume">21</span>(4):259‐71. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15012171" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+is+effective+therapy+for+elderly+patients+with+type+2+diabetes+mellitus&author=R+Rajagopalan&author=A+Perez&author=Z+Ye&author=M+Khan&author=FT+Murray&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Rajagopalan 2005a</h4> </div> <div class="bibliography-section" id="CD006060-bib-0108"> <div class="citation-journal">Rajagopalan R, Iyer S, Perez A. <span class="citation-title">Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">2005</span>;<span class="volume">7</span>(2):161‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+pioglitazone+with+other+antidiabetic+drugs+for+associated+incidence+of+liver+failure:+no+evidence+of+increased+risk+of+liver+failure+with+pioglitazone+&author=R+Rajagopalan&author=S+Iyer&author=A+Perez&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Rajagopalan 2005b</h4> </div> <div class="bibliography-section" id="CD006060-bib-0109"> <div class="citation-journal">Rajagopalan R, Iyer S, Khan M. <span class="citation-title">Effect of pioglitazone on metabolic syndrome risk factors: results of double‐blind, multicenter, randomized clinical trials</span>. <span class="citation"> Current Medical Research &amp; Opinion </span><span class="pubYear">2005</span>;<span class="volume">21</span>(1):163‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pioglitazone+on+metabolic+syndrome+risk+factors:+results+of+double%E2%80%90blind,+multicenter,+randomized+clinical+trials+&author=R+Rajagopalan&author=S+Iyer&author=M+Khan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Richter 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0110"> <div class="citation-journal">Richter B, Neises G. <span class="citation-title">'Human' insulin versus animal insulin in people with diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15674916" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title='Human'+insulin+versus+animal+insulin+in+people+with+diabetes+mellitus&author=B+Richter&author=G+Neises&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">Roberts 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0111"> <div class="citation-journal">Roberts D, Van NW, Chang H, Pohula W, MCheang, Moffatt M, et al. <span class="citation-title">Glargine versus other basal insulins (NPH, Lente, or Ultralente) for the treatment of type 1 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glargine+versus+other+basal+insulins+(NPH,+Lente,+or+Ultralente)+for+the+treatment+of+type+1+diabetes+mellitus+&author=D+Roberts&author=NW+Van&author=H+Chang&author=W+Pohula&author=+MCheang&author=M+Moffatt&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">Roden 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0112"> <div class="citation-journal">Roden M, Laakso M, Johns D, Widel M, Urquhart R, Richardson C, Mariz S, Tan MH. <span class="citation-title">Long‐term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(8):1101‐1106. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16026380" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+effects+of+pioglitazone+and+metformin+on+insulin+sensitivity+in+patients+with+Type+2+diabetes+mellitus+&author=M+Roden&author=M+Laakso&author=D+Johns&author=M+Widel&author=R+Urquhart&author=C+Richardson&author=S+Mariz&author=MH+Tan&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">Rosenblatt 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0113"> <div class="citation-journal">Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Corbin RP, et al. <span class="citation-title">The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus</span>. <span class="citation"> Coronary Artery Disease </span><span class="pubYear">2001</span>;<span class="volume">12</span>(5):413‐23. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11491207" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+pioglitazone+on+glycemic+control+and+atherogenic+dyslipidemia+in+patients+with+type+2+diabetes+mellitus+&author=S+Rosenblatt&author=B+Miskin&author=NB+Glazer&author=MJ+Prince&author=KE+Robertson&author=RP+Corbin&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">Rosenstock 2002</h4> </div> <div class="bibliography-section" id="CD006060-bib-0114"> <div class="citation-journal">Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. <span class="citation-title">Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo‐controlled study in patients receiving stable insulin therapy</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2002</span>;<span class="volume">56</span>(4):251‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12074206" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+pioglitazone+in+type+2+diabetes:+A+randomised,+placebo%E2%80%90controlled+study+in+patients+receiving+stable+insulin+therapy+&author=J+Rosenstock&author=D+Einhorn&author=K+Hershon&author=NB+Glazer&author=S+Yu&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">Royle 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0115"> <div class="citation-journal">Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. <span class="citation-title">Inhaled insulin in diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2003</span>, Issue 4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Inhaled+insulin+in+diabetes+mellitus&author=P+Royle&author=N+Waugh&author=L+McAuley&author=L+McIntyre&author=S+Thomas&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">Ruige 1997</h4> </div> <div class="bibliography-section" id="CD006060-bib-0116"> <div class="citation-journal">Ruige JB, deNeeling JND, Kostense PJ, Bouter LM, Heine RJ. <span class="citation-title">Performance of an NIDDM screening questionnaire based on symptoms and risk factors</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1997</span>;<span class="volume">20</span>:491–6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9096967" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Performance+of+an+NIDDM+screening+questionnaire+based+on+symptoms+and+risk+factors&author=JB+Ruige&author=JND+deNeeling&author=PJ+Kostense&author=LM+Bouter&author=RJ+Heine&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Saenz 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0117"> <div class="citation-journal">Saenz A, Fernandez‐Esteban I, Mataix A, Ausejo M, Roque M, Moher D. <span class="citation-title">Metformin monotherapy for type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16034881" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metformin+monotherapy+for+type+2+diabetes+mellitus&author=A+Saenz&author=I+Fernandez%E2%80%90Esteban&author=A+Mataix&author=M+Ausejo&author=M+Roque&author=D+Moher&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">Salpeter 2003</h4> </div> <div class="bibliography-section" id="CD006060-bib-0118"> <div class="citation-journal">Salpeter S, Greyber E, Pasternak G, Salpeter E. <span class="citation-title">Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2003</span>, Issue 3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12804446" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+of+fatal+and+nonfatal+lactic+acidosis+with+metformin+use+in+type+2+diabetes+mellitus&author=S+Salpeter&author=E+Greyber&author=G+Pasternak&author=E+Salpeter&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0110"> <div class="reference-title-banner"> <h4 class="title">Siebenhofer 2004</h4> </div> <div class="bibliography-section" id="CD006060-bib-0119"> <div class="citation-journal">Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. <span class="citation-title">Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2004</span>, Issue 4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Short+acting+insulin+analogues+versus+regular+human+insulin+in+patients+with+diabetes+mellitus+&author=A+Siebenhofer&author=J+Plank&author=A+Berghold&author=M+Narath&author=R+Gfrerer&author=TR+Pieber&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0111"> <div class="reference-title-banner"> <h4 class="title">Skyler 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0120"> <div class="citation-journal">Skyler JS. <span class="citation-title">PROactive results overstated and misleading</span>. <span class="citation"> DOC News </span><span class="pubYear">2005</span>;<span class="volume">2</span>:4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=PROactive+results+overstated+and+misleading&author=JS+Skyler&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0112"> <div class="reference-title-banner"> <h4 class="title">Skyler 2006</h4> </div> <div class="bibliography-section" id="CD006060-bib-0121"> <div class="citation-journal">Skyler JS. <span class="citation-title">PROactive: A Sad Tale of Inappropriate Analysis and Unjustified Interpretation</span>. <span class="citation"> CLINICAL DIABETES </span><span class="pubYear">2006</span>;<span class="volume">24</span>:63‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=PROactive:+A+Sad+Tale+of+Inappropriate+Analysis+and+Unjustified+Interpretation&author=JS+Skyler&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0113"> <div class="reference-title-banner"> <h4 class="title">Stamler 1993</h4> </div> <div class="bibliography-section" id="CD006060-bib-0122"> <div class="citation-journal">Stamler J, Vaccaro O, Neaton JD, Wentworth D. <span class="citation-title">Diabetes, other risk factors, and 12‐year cardiovascular mortality for men screened in the multiple risk factor intervention trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1993</span>;<span class="volume">16</span>:434‐44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8432214" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetes,+other+risk+factors,+and+12%E2%80%90year+cardiovascular+mortality+for+men+screened+in+the+multiple+risk+factor+intervention+trial+&author=J+Stamler&author=O+Vaccaro&author=JD+Neaton&author=D+Wentworth&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0114"> <div class="reference-title-banner"> <h4 class="title">Sterne 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0123"> <div class="citation-book">Sterne JAC, Egger M, Davey Smith G. <span class="citation-title">Investigating and dealing with publication and other biases</span>. In: Egger M, Davey Smith G, Altman DG editor(s). <span class="citation">Systematic Reviews in Health Care; Meta‐analysis in Context</span>. London: BMJ Publishing Group, <span class="pubYear">2001</span>:189‐208. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Investigating+and+dealing+with+publication+and+other+biases&author=JAC+Sterne&author=M+Egger&author=G+DaveySmith&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0115"> <div class="reference-title-banner"> <h4 class="title">Stratton 2000</h4> </div> <div class="bibliography-section" id="CD006060-bib-0124"> <div class="citation-journal">Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. <span class="citation-title">Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</span>. <span class="citation"> BMJ </span><span class="pubYear">2000</span>;<span class="volume">321</span>(7258):405‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10938048" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+of+glycaemia+with+macrovascular+and+microvascular+complications+of+type+2+diabetes+(UKPDS+35):+prospective+observational+study+&author=IM+Stratton&author=AI+Adler&author=HA+Neil&author=DR+Matthews&author=SE+Manley&author=CA+Cull&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0116"> <div class="reference-title-banner"> <h4 class="title">Tan 2004c</h4> </div> <div class="bibliography-section" id="CD006060-bib-0125"> <div class="citation-journal">Tan MH, Johns D, Glazer NB. <span class="citation-title">Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes</span>. <span class="citation"> Clinical Chemistry </span><span class="pubYear">2004</span>;<span class="volume">50</span>(7):1184‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15117857" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+reduces+atherogenic+index+of+plasma+in+patients+with+type+2+diabetes&author=MH+Tan&author=D+Johns&author=NB+Glazer&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0117"> <div class="reference-title-banner"> <h4 class="title">Tan 2004d</h4> </div> <div class="bibliography-section" id="CD006060-bib-0126"> <div class="citation-journal">Tan MH, Glazer NB, Johns D, Widel M, Gilmore KJ. <span class="citation-title">Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA‐S or QUICKI) in patients with type 2 diabetes</span>. <span class="citation"> Current Medical Research &amp; Opinion </span><span class="pubYear">2004</span>;<span class="volume">20</span>(5):723‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+as+monotherapy+or+in+combination+with+sulfonylurea+or+metformin+enhances+insulin+sensitivity+(HOMA%E2%80%90S+or+QUICKI)+in+patients+with+type+2+diabetes+&author=MH+Tan&author=NB+Glazer&author=D+Johns&author=M+Widel&author=KJ+Gilmore&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0118"> <div class="reference-title-banner"> <h4 class="title">Tang 2000</h4> </div> <div class="bibliography-section" id="CD006060-bib-0127"> <div class="citation-journal">Tang JL, Liu JLY. <span class="citation-title">Misleading funnel plot for detection of bias in meta‐analysis</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2000</span>;<span class="volume">53</span>:477‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10812319" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Misleading+funnel+plot+for+detection+of+bias+in+meta%E2%80%90analysis&author=JL+Tang&author=JLY+Liu&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0119"> <div class="reference-title-banner"> <h4 class="title">Thomas 2001</h4> </div> <div class="bibliography-section" id="CD006060-bib-0128"> <div class="citation-journal">Thomas D, Elliott E. <span class="citation-title">Exercise for type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2001</span>, Issue 1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exercise+for+type+2+diabetes+mellitus&author=D+Thomas&author=E+Elliott&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0120"> <div class="reference-title-banner"> <h4 class="title">Thornton 2000</h4> </div> <div class="bibliography-section" id="CD006060-bib-0129"> <div class="citation-journal">Thornton A, Lee P. <span class="citation-title">Publication bias in meta‐analysis: its causes and consequences</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2000</span>;<span class="volume">53</span>:207‐16. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10729693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Publication+bias+in+meta%E2%80%90analysis:+its+causes+and+consequences&author=A+Thornton&author=P+Lee&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0121"> <div class="reference-title-banner"> <h4 class="title">UGDP 1982</h4> </div> <div class="bibliography-section" id="CD006060-bib-0130"> <div class="citation-journal">University Group Diabetes Program. <span class="citation-title">Effects of hypoglycemic agents on vascular complications in patients with adult‐onset diabetes, VIII. Evaluation of insulin therapy: final report</span>. <span class="citation"> Diabetes </span><span class="pubYear">1982</span>;<span class="volume">31 Suppl 5</span>:1‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6757026" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0122"> <div class="reference-title-banner"> <h4 class="title">UKPDS‐16 1995</h4> </div> <div class="bibliography-section" id="CD006060-bib-0131"> <div class="citation-journal">U.K. Prospective Diabetes Study Group. <span class="citation-title">U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease</span>. <span class="citation"> Diabetes </span><span class="pubYear">1995</span>;<span class="volume">44</span>:1249‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7589820" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0123"> <div class="reference-title-banner"> <h4 class="title">UKPDS‐33 1998</h4> </div> <div class="bibliography-section" id="CD006060-bib-0132"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes‐UKPDS 33</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>:837‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742976" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0124"> <div class="reference-title-banner"> <h4 class="title">UKPDS‐34 1998</h4> </div> <div class="bibliography-section" id="CD006060-bib-0133"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>:854‐65. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742977" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0125"> <div class="reference-title-banner"> <h4 class="title">UKPDS‐38 1998</h4> </div> <div class="bibliography-section" id="CD006060-bib-0134"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):703‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732337" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0126"> <div class="reference-title-banner"> <h4 class="title">Van de Laar 2005</h4> </div> <div class="bibliography-section" id="CD006060-bib-0135"> <div class="citation-journal">Laar FA, Lucassen PLBJ, Akkermans RP, Lisdonk EH, Rutten GEHM, Van WC. <span class="citation-title">Alpha‐glucosidase inhibitors for type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2005</span>, Issue 2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15846673" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alpha%E2%80%90glucosidase+inhibitors+for+type+2+diabetes+mellitus&author=FA+Laar&author=PLBJ+Lucassen&author=RP+Akkermans&author=EH+Lisdonk&author=GEHM+Rutten&author=WC+Van&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0127"> <div class="reference-title-banner"> <h4 class="title">Warram 1990</h4> </div> <div class="bibliography-section" id="CD006060-bib-0136"> <div class="citation-journal">Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. <span class="citation-title">Slow glucose removal rate and hyperinsulinemia precede the development of Type 2 diabetes in the offspring of diabetic parents</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">1990</span>;<span class="volume">113</span>:909–15. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2240915" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Slow+glucose+removal+rate+and+hyperinsulinemia+precede+the+development+of+Type+2+diabetes+in+the+offspring+of+diabetic+parents+&author=JH+Warram&author=BC+Martin&author=AS+Krolewski&author=JS+Soeldner&author=CR+Kahn&publication_year=1990&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0128"> <div class="reference-title-banner"> <h4 class="title">Waugh 2006</h4> </div> <div class="bibliography-section" id="CD006060-bib-0137"> <div class="citation-journal">Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. <span class="citation-title">Pioglitazone: a review of its use in type 2 diabetes mellitus</span>. <span class="citation"> Drugs </span><span class="pubYear">2006</span>;<span class="volume">66</span>(1):85‐109. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16398569" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone:+a+review+of+its+use+in+type+2+diabetes+mellitus&author=J+Waugh&author=GM+Keating&author=GL+Plosker&author=S+Easthope&author=DM+Robinson&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0129"> <div class="reference-title-banner"> <h4 class="title">WHO 1980</h4> </div> <div class="bibliography-section" id="CD006060-bib-0138"> <div class="citation-other">WHO Expert Committee on Diabetes Mellitus. <span class="citation-title">Second report. Technical Report Series 646</span>. Geneva. WHO, 1980. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0130"> <div class="reference-title-banner"> <h4 class="title">WHO 1985</h4> </div> <div class="bibliography-section" id="CD006060-bib-0139"> <div class="citation-other"><span class="citation-title">WHO Expert Committee on Diabetes Mellitus</span>. World Health Organization, 1985. Technical Report Series 727. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006060-bbs2-0131"> <div class="reference-title-banner"> <h4 class="title">WHO 1998</h4> </div> <div class="bibliography-section" id="CD006060-bib-0140"> <div class="citation-journal">Alberti KM, Zimmet PZ. <span class="citation-title">Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1998</span>;<span class="volume">15</span>:539‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9686693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Definition,+diagnosis+and+classification+of+diabetes+mellitus+and+its+compliactions.+Part+I:+diagnosis+and+classification+of+diabetes+mellitus.+Provisional+report+of+a+WHO+consultation+&author=KM+Alberti&author=PZ+Zimmet&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD006060-sec2-0033"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006060-sec2-0034" class="jump-to">excluded studies</a></li> <li><a href="#CD006060-sec2-0035" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Aronoff 2000 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 26 weeks <br> DURATION OF FOLLOW‐UP: <br> 26 weeks <br> RUN‐IN PERIOD: <br> ‐ 6 ‐8 weeks single‐blind washout period, including 2 weeks for baseline measurements. <br> ‐ patients who had never received pharmacological antidiabetic therapy were enrolled in the study and entered a 6‐week single‐blind run‐in period <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> 78% white patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> type 2 diabetes; HbA1c &gt;= 7.0%, FPG &gt;=140 mg/dl; fasting C‐peptide &gt;1 ng/ml <br> EXCLUSION CRITERIA: <br> chronic insulin use; history of ketoacidosis; unstable or progressive diabetic retinopathy, nephropathy, neuropathy; impaired liver function; impaired kidney function; anaemia; within 6 months of the study: myocardial infarction, coronary angioplasty or bypass graft, unstable angina, transient ischaemic attacks, documented cerebrovascular accident <br> DIAGNOSTIC CRITERIA: <br> HbA1c &gt;= 7.0%, FPG &gt;=140 mg/dl; fasting C‐peptide &gt;1 ng/ml <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 35 <br> COUNTRY/ LOCATION: <br> all regions of the USA <br> SETTING: <br> unclear; investigators consisted of board‐certified endocrinologists and primary care physicians in academic and nonacademic sites <br> INTERVENTION (DOSE/DAY): <br> pioglitazone 7.5, 15, 30, 45 mg/day (four groups) <br> CONTROL (DOSE/DAY): <br> placebo <br> TREATMENT BEFORE STUDY: <br> ‐ most commonly sulphonylureas (glyburide and gliclazide), 13% had received 2 or more antidiabetic medications. <br> ‐ discontinuation of prior antidiabetic medication at the beginning of the washout period (i.e. 8 weeks before receiving double‐blind treatment). <br> no required modifications of current dietary regimens during the study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> not stated (HbA1c) <br> SECONDARY OUTCOMES: <br> lipid parameters, FPG, safety assessment and adverse effects </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to assess the metabolic effects of 4 doses of pioglitazone monotherapy in the treatment of patients with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Charbonnel 2005a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 52 weeks <br> DURATION OF FOLLOW‐UP: <br> 52 weeks <br> RUN‐IN PERIOD: <br> not stated <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> drug‐naive patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> 35‐75 years, type 2 diabetes inadequately controlled with diet alone, HbA1c 7.5‐11% with stable or worsening glycaemic control over a period of at least 3 months; if antihypertensive treatment was indicated during the study, patients were treated with ACE inhibitors or Ca antagonists <br> EXCLUSION CRITERIA: <br> previous glucose‐lowering medication, specific contraindications to either drug; long‐term treatment with corticosteroids, start of beta‐blockers not permitted during study or within 4 weeks prior to screening <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> if antihypertensive treatment was indicated during the study, patients were treated with ACE inhibitors or Ca antagonists. 14% of patients in each group were receiving treatment with beta‐blockers at baseline </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 219 <br> COUNTRY/ LOCATION: <br> 14 European countries, Canada, South Africa and Israel <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; up to 45 mg/day (reached by 80.7%, mean dose 42 mg/day) <br> CONTROL (DOSE/DAY): <br> glicliazide; up to 320 mg/day (reached by 27.9%, mean dose 198 mg/day) <br> TREATMENT BEFORE STUDY: <br> ‐ patients treated with diet alone prior to intervention. dietary advice was given at baseline with the target of body weight normalization. <br> ‐ 14% in each group taking beta‐blockers at baseline (exclusion criterion!) <br> Both groups: <br> dietary advice given at baseline with target of body weight normalisation; if body weight increased more than 5% during treatment or HbA1c increased to greater than 9% after completed dose titration, patients were given further intensive dietary advice <br> TITRATION: <br> 16‐week forced‐titration period to a maximum dose and a 36‐week maintenance period at the maximum tolerated dose of drug </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> HbA1c (change from baseline to last available post‐treatment value) <br> SECONDARY OUTCOMES: <br> FPG, insulin, plasma lipids, C‐peptide, pro‐insulin, adverse effects </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the effects of of pioglitazone and gliclazide on metabolic control in drug‐naive patients with type 2 diabetes mellitus </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Derosa 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 12 months <br> DURATION OF FOLLOW‐UP: <br> 12 months <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> white patients with type 2 diabetes mellitus and metabolic syndrome <br> INCLUSION CRITERIA: <br> white patients of either sex and ages &gt;=18 years; type 2 diabetes according to ADA criteria (duration &gt;=6 months); poor glycaemic control (HbA1c &gt;=7.5% or &gt;=1 adverse effect with diet and oral hypoglycaemic agents (e.g. SU or metformin) given up to the maximum tolerated dose; all patients also diagnosed with metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III classification; triglyceridaemia (TG &gt;=150 mg/dl) and hypertension (WHO criteria BP &gt;=130/&gt;=85 mmHg); fasting C‐peptide level &gt;1.0 ng/ml <br> EXCLUSION CRITERIA: <br> receiving glimepiride, history of ketoacidosis, unstable or rapidly progressive diabetic retinopathy, nephropathy or neuropathy; impaired hepatic function, impaired renal function, severe anaemia; severe cardiovascular disease (e.g. NYHA class III or IV congestive heart failure or a history of myocardial infarction or stroke) or cerebrovascular conditions within 6 months before enrolment; women who were pregnant or breastfeeding or of childbearing potential and not taking adequate contraceptive precautions <br> DIAGNOSTIC CRITERIA: <br> ADA 2001 <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> 40.2% receiving antihypertensive drugs. no patient was receiving lipid‐lowering or antiaggregant drugs </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> three <br> COUNTRY/ LOCATION: <br> Italy <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 15 mg once daily; + fixed oral dose of glimepiride (4 mg/day divided into 2 doses) <br> CONTROL (DOSE/DAY): <br> rosiglitazone; 4 mg once daily; +fixed oral dose of glimepiride (4 mg/day divided into 2 doses) <br> TREATMENT BEFORE STUDY: <br> 52.9% poor glycaemic control with metformin; 31% with SUs; 16.1% with glyburide; 14.9% with gliclazide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> changes in BMI, HbA1c, lipid profile, and lipoprotein variables were the primary efficacy variables <br> SECONDARY OUTCOMES: <br> fasting and postprandial plasma glucose, insulin levels, insulin resistance (HOMA); blood pressure; adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to assess the differential effect on glucose and lipid variables of the combination of glimepiride plus pioglitazone or rosiglitazone in patients with type 2 diabetes and the metabolic syndrome </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Adequate</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Derosa 2006 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 12 months <br> DURATION OF FOLLOW‐UP: <br> 12 months <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> white patients with type 2 diabetes mellitus and metabolic syndrome <br> INCLUSION CRITERIA: <br> white patients of either sex and ages &gt;=18 years; type 2 diabetes according to ADA criteria (duration &gt;=6 months); poor glycaemic control (HbA1c &gt;=7.5% or adverse effects with diet and metformin given up to the maximum tolerated dose; all patients also diagnosed with metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III classification; triglyceridaemia (TG &gt;=150 mg/dl) and hypertension (WHO criteria BP &gt;=130/&gt;=85 mmHg); fasting C‐peptide level &gt;1.0 ng/ml; overweight (BMI 25.0‐28.1 kg/m2) <br> EXCLUSION CRITERIA: <br> history of ketoacidosis, unstable or rapidly progressive diabetic retinopathy, nephropathy or neuropathy; impaired hepatic function, impaired renal function, severe anaemia; severe cardiovascular disease (e.g. NYHA class I to IV congestive heart failure or a history of myocardial infarction or stroke) or cerebrovascular conditions within 6 months before enrolment; women who were pregnant or breastfeeding or of childbearing potential and not taking adequate contraceptive precautions <br> DIAGNOSTIC CRITERIA: <br> ADA 2001 <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> not stated </p> <p>‐ at baseline, patients began a <br> controlled‐energy diet (600 kcal daily deficit), based on ADA recommendations; <br> ‐ every 2 weeks dietitians and/or <br> specialists provided instructions on dietary intake which was part of a behaviour‐modification programme; <br> ‐ during the study, behaviour‐modification <br> sessions on weight‐loss strategies were given to individual patients at baseline and at 6 months, and as a group at 3, 6, 9 and 12 months; <br> ‐ individuals were also encouraged to increase their physical activity by walking briskly or riding a stationary bicycle for 20–30 min, three to five <br> times a week. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> three <br> COUNTRY/ LOCATION: <br> Italy <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 15 mg once daily; + metformin up to 3000 mg/day <br> CONTROL (DOSE/DAY): <br> rosiglitazone; 4 mg once daily; +metformin up to 3000 mg/day <br> METFORMIN DOSE (both groups): <br> mean dosage 2250 mg +‐ 750 mg/day <br> TREATMENT BEFORE STUDY: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> changes in lipoprotein a and homocystein levels from baseline to the end of 12 months <br> SECONDARY OUTCOMES: <br> HbA1c; fasting and postprandial plasma glucose, insulin levels, insulin resistance (HOMA); lipid profile; BMI; adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to evaluate the differential effect on homocysteine and lipoprotein a plasma levels of the two combinations, metformin plus pioglitazone and metformin plus rosiglitazone, in patients with <br> type 2 diabetes </p> <p>‐ patients were required to have poor glycaemic control with diet, or experienced adverse effects with diet and metformin, administered up to the maximum tolerated dose <br> (comment: if individuals experienced side effects of metformin treatment, how could they be randomised to metformin plus additional pioglitazone or rosiglitazone treatment?) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Adequate</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Dormandy 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 34.5 months (mean) <br> DURATION OF FOLLOW‐UP: <br> 34.5 months (mean) <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus who had evidence of macrovascular disease <br> INCLUSION CRITERIA: <br> patients with type 2 diabetes aged 35–75 years; HBA1c greater than the local laboratory equivalent of 6·5% for a Diabetes Control and Complications Trial‐traceable assay (DCCT), despite existing treatment with diet alone or with oral glucose‐lowering agents with or without insulin. evidence of macrovascular disease before recruitment, defined by one or more of the following criteria: myocardial infarction or stroke at least 6 months before entry to the trial, percutaneous coronary intervention or coronary artery bypass surgery at least 6 months before recruitment, acute coronary syndrome at least 3 months before recruitment, or objective evidence of coronary artery disease or obstructive arterial disease in the leg. Objective evidence of coronary artery disease was defined as a positive exercise test, angiography showing at least one stenosis of more than 50%, or positive scintigraphy. obstructive arterial disease of the leg was defined as a previous major amputation or intermittent claudication with an ankle or toe brachial pressure index of less than 0·9 <br> EXCLUSION CRITERIA: <br> type 1 diabetes; taking only insulin; planned coronary or peripheral revascularisation; NYHA II class II heart failure or above; ischaemic ulcers, gangrene, or rest pain in the leg; haemodialysis; greater than 2·5 times the upper limit of ALAT. <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> Intervention vs control: <br> ‐ history of hypertension 75% vs 76%; <br> ‐ current smoker 13% vs 14%; <br> ‐ past smoker 46% vs 44%; <br> ‐ microvascular disease (retinopathy, nephropathy, neuropathy) 43% vs 41%. <br> ‐ previous myocardial infarction 47% vs 46%; <br> ‐ previous stroke 19% vs 19%; <br> ‐ previous percutaneous intervention or coronary artery bypass graft 31% vs 31%; <br> ‐ previous acute coronary syndrome 14% vs 14%; <br> ‐ objective evidence of coronary artery disease 48% vs 48%; <br> ‐ symptomatic peripheral arterial obstructive disease 19% vs 20%; <br> ‐ two or more macrovascular disease criteria 47% vs 49%. <br> CO‐MEDICATIONS: <br> Intervention vs control: <br> ‐ beta‐blockers 55% vs 54%; <br> ‐ ACE inhibitors 63% vs 63%; <br> ‐ AT II antagonists 7% vs7% <br> ‐ Ca‐channel blockers 34% vs 37%; <br> ‐ nitrates 39% vs 40%; <br> ‐ thiazide diuretics 15% vs 16%; <br> ‐ loop diuretics 14% vs 14%; <br> ‐ antiplatelet medications 85% vs 83%; <br> ‐ aspirin 75% vs 72%; <br> ‐ statins 43% vs 43%; <br> ‐ fibrates 10% vs 11%. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 321 <br> COUNTRY/ LOCATION: <br> 19 European countries <br> SETTING: <br> recruitment from community (1681 patients) and hospitals (3557 patients) <br> INTERVENTION (DOSE/DAY): <br> pioglitazone titrated from 15 mg to 45 mg in addition to other glucose‐lowering drugs and other medications <br> CONTROL (DOSE/DAY): <br> matching placebo in addition to other glucose‐lowering drugs and other medications <br> TREATMENT BEFORE STUDY: <br> Blood glucose lowering treatment ‐ intervention vs control: <br> ‐ metformin only 10% vs 10%; <br> ‐ sulphonylureas only 20% vs 19%; <br> ‐ metformin + sulphonylureas 25% vs 25%; <br> ‐ insulin only &lt;1% vs &lt;1% <br> ‐ insulin + metformin 18% vs 18%; <br> ‐ insulin + sulphonylureas 8% vs 8%; <br> ‐ insulin + metformin + sulphonylureas 4% vs 4%; <br> ‐ other combinations 12% vs 12%; <br> ‐ diet only 4% vs 4%. <br> TITRATION: <br> ‐ pioglitazone 15 mg for the first month, 30 mg for the second month, and 45 mg thereafter to achieve the maximum tolerated dose, according to the licensed dose range for pioglitazone (89% of patients reached the 45 mg dose at the 2‐month visit compared with 91% of matching placebo); <br> ‐ throughout the study, investigators were required to increase all therapy to an optimum, according to the International Diabetes Federation European Region 1999 guidelines. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> composite endpoint ‐ time from randomisation to all‐cause mortality, non‐fatal myocardial infarction (including silent myocardial infarction), stroke, acute coronary syndrome, endovascular or surgical intervention on the coronary or leg arteries, or amputation above the ankle <br> SECONDARY OUTCOMES: <br> LANCET publication: <br> ‐ time to the first event of the composite endpoint of death from any cause, myocardial infarction (excluding silent <br> myocardial infarction), and stroke (so‐called "main secondary endpoint" in the Lancet publication); <br> ‐ cardiovascular death; <br> ‐ time to individual components of the primary composite endpoint.; <br> DIABETES CARE publication (study design &amp; baseline characteristics): <br> ‐ individual components of the primary endpoint and cardiovascular mortality. <br> STATISTICAL ANALYSIS PLAN <br> Version 1.3 (FINAL) / 12 May 2005 AD‐4833 / Pioglitazone: <br> "The study protocol identifies the following as secondary endpoints: <br> ‐ The individual components of the primary endpoint <br> ‐ Cardiovascular mortality <br> In addition, at the time of preparation of this plan, it was decided to add one further <br> composite endpoint to the list of secondary endpoints, namely, all‐cause mortality, acute myocardial infarction (excluding silent MI) and stroke. The reason for this addition is so that the analysis can report the extent of treatment effects with respect <br> to an endpoint which is also used commonly in large cardiovascular outcome studies" <br> WWW.CLINICALTRIALS.GOV (published with identifier NCT00174993): <br> "Primary Outcomes: Time to death, non‐fatal myocardial infarction, acute coronary syndrome, cardiac intervention (PCI/CABG), stroke, leg amputation, revascularisation in the leg. Minimum 30 months follow up <br> Secondary Outcomes: Adverse events" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to ascertain whether pioglitazone reduces <br> cardiovascular morbidity and mortality in in high‐risk patients with type 2 diabetes, and to assess the safety and tolerability of such treatment. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Adequate</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ebeling 2001 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 6 months <br> DURATION OF FOLLOW‐UP: <br> 6 months <br> RUN‐IN PERIOD: <br> not stated <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus from Helsinki University Hospital who took part in a phase III study <br> INCLUSION CRITERIA: <br> type 2 diabetes treated with diet and oral medication or diet alone; BMI &gt;=25 kg/m2, age 35‐75 years; HbA1c &gt;=7.5%, fasting serum glucose &gt;=7.8mmol/L <br> EXCLUSION CRITERIA: <br> not stated <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> mainly antihypertensives (same before and after the study) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> one <br> COUNTRY/ LOCATION: <br> Finland <br> SETTING: <br> outpatient clinics <br> INTERVENTION 1 (DOSE/DAY): <br> pioglitazone; 30 mg/day <br> Control 1 (DOSE/DAY): <br> glibenclamide; 2.5 mg/day <br> CONTROL 2 (DOSE/DAY): <br> placebo <br> TREATMENT BEFORE STUDY: <br> not stated <br> TITRATION: <br> clinics visited at 2‐6 week intervals for safety measurements; if the reduction in HbA1c at week 9 was not greater than or equal to 0.3%, antidiabetic medication was doubled in glibenclamide group (0 patients) and increased to 45 mg/day in the pioglitazone group (4 of 9 patients) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> not stated (inflammatory markers) <br> SECONDARY OUTCOMES: <br> HbA1c, C‐peptide, serum insulin, lipids, free fatty acids, fasting serum glucose, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> study of inflammatory factors in type 2 diabetes: <br> 1.are inflammatory factors and activation of the complement system related? <br> 2.how does improvement of glycaemic control by pioglitazone or glibenclamide affect concentrations of acute phase seroproteins? <br> 3.is improved metabolic control related to changes in complement activation? </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Goke 2002 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 26 weeks +‐ 5 days <br> DURATION OF FOLLOW‐UP: <br> 26 weeks +‐ 5 days <br> RUN‐IN PERIOD: <br> ‐ one week with disease‐ and bodyweight‐oriented dietary regimen; patients were asked to continue with recommended diet throughout the study <br> ‐ for acarbose, titration phase 3 weeks starting at 50 mg once daily up to 300 mg daily administered in 3 doses <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients were either newly diagnosed with type 2 diabetes mellitus or had previous treatment with oral antihyperglycaemic drugs <br> INCLUSION CRITERIA: <br> type 2 diabetes, newly diagnosed or previous treatment with oral antidiabetic drugs; diabetes not well controlled with HbA1c 7.5‐11.5%, FPG &gt;=140 mg/dl, BMI 25‐43 kg/m2 <br> EXCLUSION CRITERIA: <br> insulin dependent diabetes, required other specific antidiabetic drugs, history of ketoacidosis, disease causing malabsorption or digestive problems, history of heart disease, haematological disease or HIV infection, evidence of liver, kidney or bone marrow impairment <br> patients were discontinued if HbA1c levels were &gt;11.5% or FPG &gt;250 mg/dl for more than 3 months, if clinical complications of diabetes occurred or if adverse events occurred <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 47 <br> COUNTRY/ LOCATION: <br> Germany <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 45 mg/day <br> CONTROL (DOSE/DAY): <br> acarbose; starting at 50 mg once daily up to 300 mg daily administered in 3 doses <br> TREATMENT BEFORE STUDY: <br> ‐ 27.9% on metformin, 24.9% on sulphonylureas; <br> ‐ patients previously on oral antidiabetics (intervention 46.5%, control 47.8%) had to discontinue those 2 months prior to starting the study. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> not stated (HbA1c) <br> SECONDARY OUTCOMES: <br> FPG, fasting insulin, C‐peptide, HOMA: insulin resistance, triglycerides, total cholesterol, HDL‐, LDL‐, VLDL‐cholesterol, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> ‐ to examine the efficacy of of pioglitazone compared with acarbose treatment in patients with type 2 diabetes mellitus, either newly diagnosed or previously treated but not well controlled; effects on glycaemic parameters, lipid profiles and safety; </p> <p>‐ at the end of the 26 weeks of study, patients receiving pioglitazone could continue with the same treatment and those receiving acarbose could start taking pioglitazone in addition to the acarbose, for a further 38‐week extension period. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Goldberg 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 24 weeks <br> DURATION OF FOLLOW‐UP: <br> 24 weeks <br> RUN‐IN PERIOD: <br> oral placebo; single‐blind; 4 weeks <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus who were treated with diet alone or oral monotherapy <br> INCLUSION CRITERIA: <br> men or women &gt;= 35 years of age with a diagnosis of type 2 diabetes (WHO) with fasting triglyceride levels &gt;= 150 mg/dl and&lt; 600 mg/dl and fasting LDL cholesterol levels &lt; 130 mg/dl; fasting serum C‐peptide levels <br> &gt;= 1 ng/ml and HbA1c values &gt;= 7 and &lt;= 11% if naive to previous oral antihyperglycemic therapy or HbA1c values &gt;= 7 and &lt;= 9.5% if previously treated with oral antihyperglycemic monotherapy. <br> EXCLUSION CRITERIA: <br> treatment within 60 days of screening with insulin, systemic glucocorticoid therapy; combination oral antihyperglycemic therapy, any lipid‐lowering agent, or any weight loss agent; known allergy to any thiazolidinedione; serum creatinine &gt;= 176.8 µmol/dl (&gt;= 2.0 mg/dl) or 2+ dipstick proteinuria at screening; ALT or AST &gt;= 1.5 times the upper limit of normal or significant clinical liver disease; hemoglobin &lt; 10.5 g/dl (females) or &lt; 11.5 g/dl (males) at screening; abnormal <br> thyrotropin; functional NYHA class III or IV, history of CVD, or heart surgery within 6 months of screening; receiving renal dialysis or having renal transplant; current therapy for malignancy other than basal cell or squamous cell skin cancer; known history of HIV infection; signs or symptoms of drug or alcohol abuse; any condition or situation precluding adherence to and completion of the protocol. For female subjects, appropriate birth control was required, and pregnancy, breast‐feeding, or the intent to become pregnant during the study period prohibited participation. <br> DIAGNOSTIC CRITERIA: <br> WHO <br> CO‐MORBIDITIES: <br> intervention 1 vs control 1: <br> ‐ pre‐existing CVD or previous myocardial infarction 8.4% vs 6.6% <br> CO‐MEDICATIONS: <br> intervention 1 vs control 1: <br> ‐ metformin 45.8% vs 44.7%; <br> ‐ insulin secretagogues (including ‐ repaglinide and nateglinide) 45.8% vs 46.1%; <br> ‐ thiazolidinediones 8.5% vs 9.2%. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 100 (USA 78) <br> COUNTRY/ LOCATION: <br> USA, Puerto Rico, Mexico, Colombia <br> SETTING: <br> unclear <br> INTERVENTION 1(DOSE/DAY): <br> pioglitazone; 30 mg daily for 12 weeks; thereafter 45 mg once daily for 12 weeks <br> CONTROL 1 (DOSE/DAY): <br> rosiglitazone; 4 mg daily for 12 weeks; thereafter 4 mg twice daily (8 mg/day) for 12 weeks <br> TREATMENT BEFORE STUDY: <br> participants discontinued any current oral antihyperglycaemic treatment <br> TITRATION: <br> ‐ pioglitazone; 30 mg daily for 12 weeks; thereafter 45 mg once daily for 12 weeks <br> ‐ rosiglitazone; 4 mg daily for 12 weeks; thereafter 4 mg twice daily (8 mg/day) for 12 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> triglycerides change from baseline to the last observed value <br> SECONDARY OUTCOMES: <br> total cholesterol; plasma glucose; free fatty acids; apolipoprotein B; total insulin; C‐peptide; highly sensitive C‐reactive protein; plasminogen activator inhibitor‐1 (PAI‐1); HDL‐C; LDL‐C particle size and concentration; surrogates of insulin resistance and beta‐cell function (HOMA); safety assessments including adverse events, body weight, pedal oedema and hypoglycaemic episodes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to test the hypothesis that pioglitazone has greater triglyceride‐lowering effects <br> than rosiglitazone ‐ comparison of maximally effective monotherapy doses of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia receiving no concomitant glucose‐lowering or lipid‐lowering therapies. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Hanefeld 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 52 weeks <br> DURATION OF FOLLOW‐UP: <br> 52 weeks <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> mainly white patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> age 35‐75 years, type 2 diabetes inadequately managed on sulphonylureas alone (at &gt;=50% maximal recommended dosage or at maximal tolerated dose for &gt;=3 months) and with stable or worsening glycaemic control for &gt;=3 months; HbA1c 7.5‐11.0%, fasting C‐peptide &gt;=1.5 ng/ml at screening; female patients post‐menopausal, sterilised or using adequate contraception <br> EXCLUSION CRITERIA: <br> type 1 diabetes or ketoacidosis; history of myocardial infarction, transient ischaemic attacks, or stroke in previous 6 months; symptomatic heart failure; malabsorption or pancreatitis; familial polyposis coli; malignant disease in previous 10 years; history of states associated with lactic acidosis or hypoxaemia; substance abuse; pregnant or breast‐feeding women; previous treatment with metformin, pioglitazone or other TZDs not permitted <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> thiazides allowed to treat oedema; if antihypertensive treatment indicated, ACE inhibitors, angiotensin II receptor antagonists or Ca antagonists used </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> multi, not stated <br> COUNTRY/ LOCATION: <br> various European countries, Canada <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; up to 45 mg/day + sulphonylurea at pre‐study dose <br> CONTROL (DOSE/DAY): <br> metformin; 850 mg up to 3x/day (up to 2550 mg/day) + sulphonylurea at pre‐study dose <br> TREATMENT BEFORE STUDY: <br> ‐ sulphonylurea at pre‐study level, no dose increases permitted; SU dose could only be downtitrated in case of symptomatic hypoglyceamia; <br> ‐ most commonly used SUs in both groups: glibenclamide (42%); <br> gliclazide (31%); glimepiride (19%) <br> SU use from baseline to 52 weeks remained similar in both groups and there were very few cases of dose reduction. <br> TITRATION: <br> 12 weeks forced titration: <br> ‐ intervention 1: pioglitazone up to 45 mg/day with metformin placebo; starting with pioglitazone 15 mg/day; dose levels increased at weeks 4, 8, and 12 (maximal dose reached by 62%); <br> ‐ control: metformin 850 mg with pioglitazone placebo up to three times a day (2550 mg/day); starting with metformin 850 mg/day; dose levels increased at weeks 4, 8, and 12 (55% reached maximal dose); <br> ‐ cessation or down‐titration only allowed on basis of tolerability issues, including actual hypoglycaemia or increased risk of hypoglycaemia. Maximum tolerated dose established at week 12 maintained throughout remainder of study. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> change in HbA1c from baseline to week 52 <br> SECONDARY OUTCOMES: <br> FPG, insulin, C‐peptide, lipids, 32,33 split pro‐insulin, urinary albumine and creatinine, safety parameters, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to assess the 1 year efficacy and safety of the addition of pioglitazone or metformin to existing sulphonylurea therapy in patients with inadequately controlled type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Jovanovic 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 24 weeks <br> DURATION OF FOLLOW‐UP: <br> 24 weeks <br> RUN‐IN PERIOD: <br> two week wash‐out period (with cessation of previous antidiabetic medication) <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> mainly white patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> participants &gt;=18 years, BMI &lt;45 kg/m2, had type 2 diabetes for at least 12 months, with HbA1c &gt;7% and &lt;12%; previously treated with sulphonylurea or metformin (at 50% or more of max recommended dose) for at least 3 months <br> EXCLUSION CRITERIA: <br> patients treated within the previous 3 months with: insulin, repaglinide, TZDs, alpha‐glucosidase inhibitors, combination therapy with antidiabetic medications. <br> treatment discontinued for unacceptable hyperglycaemia (FPG above 270 mg/dl on 2 or more consecutive occasions in spite of dose escalations to the maximum allowed dosages), in absence of treatable intercurrent illness <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> multi, not stated <br> COUNTRY/ LOCATION: <br> USA <br> SETTING: <br> unclear <br> INTERVENTION 1 (DOSE/DAY): <br> pioglitazone; 30 mg/day <br> CONTROL 1 (DOSE/DAY): <br> repaglinide; dosage adjusted up to max of 4 mg/meal (target FPG values of 80‐120 mg/dl), median final dose 6.0 mg/day <br> CONTROL 2 (DOSE/DAY): <br> repaglinide+pioglitazone; pioglitazone 30 mg/day, repaglinide adjusted as above, median final dose 10.0 mg/day <br> TREATMENT BEFORE STUDY: <br> sulphonylurea or metformin <br> TITRATION: <br> ‐ for repaglinide: 12 weeks of dose optimisation ‐ repaglinide monotherapy initiated at 0.5 mg/meal if HbA1c was at 8% or below, or at 1mg per meal for all other patients; <br> ‐ in repaglinide/pioglitazone combination therapy, repaglinide as above, plus 30 mg q.d. pioglitazone; patients receiving repaglinide had dosage adjusted to achieve FPG values of 80‐120 mg/dl. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> changes in HbA1c values from baseline to the end of study treatment <br> SECONDARY OUTCOMES: <br> FPG, lipids, adverse events, hypoglycaemia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to assess the efficacy, safety and tolerability of the repaglinide+pioglitazone combination therapy in comparison to monotherapy with either agent after unsatisfactory response to sulphonylurea or metformin monotherapy </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Langenfeld 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 24 weeks +‐ 4 weeks <br> DURATION OF FOLLOW‐UP: <br> 24 weeks <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> type 2 diabetes, treated with oral antidiabetic agents, but never received TZDs; age 40‐75 years; HbA1c &gt;=6.6% and &lt;=9.9% <br> EXCLUSION CRITERIA: <br> significant hepatic or renal disease; congestive heart failure (NYHA class II to IV), smoking at time of randomisation and during previous 6 months; carotid artery stenosis <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> ‐ intervention: statins 20.2% at start, 32.8% at end; renin‐angiotensin inhibiting substances 58.4% at start, 60.7% at end; antiplatelet therapy 28.1% at start, 39.3% at end; <br> ‐ control: statins 15.5% at start, 15.5% at end; renin‐angiotensin inhibiting substances 48.8% at start, 51.2% at end; antiplatelet therapy 31.0% at start, 40.5% at end; <br> ‐ other additional antidiabetic medication, including SU but not metformin was allowed in the pioglitazone group; in the glimepiride group all kinds of other antidiabetic medication except TZDs were allowed. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> one <br> COUNTRY/ LOCATION: <br> Germany <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone 45 mg/day <br> CONTROL (DOSE/DAY): <br> glimepiride 1 to 6 mg/day, <br> average dose 2.7+‐1.6 mg <br> TREATMENT BEFORE STUDY: <br> ‐ intervention: 65.2% monotherapy, 34.8% combination therapy; <br> ‐control: 63.1% monotherapy, 36.9% combination therapy. <br> TITRATION: <br> glimepiride titrated from 1 mg to 6 mg/day for optimal glycaemic control; duration of titration period not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> not stated (carotid intima media thickness) <br> SECONDARY OUTCOMES: <br> HbA1c, fasting serum glucose, fasting serum insulin, HOMA: insulin resistance, BMI, blood pressure, lipid parameters, highly‐sensitive C‐reactive protein; von Willebrand factor </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to investigate whether pioglitazone therapy decreases carotid intima media thickness in patients with type 2 diabetes (glimepirid‐based comparison group used to compensate for concomitant effects of metabolic control) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lawrence 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 6 months <br> DURATION OF FOLLOW‐UP: <br> 6 months <br> RUN‐IN PERIOD: <br> 3 months with dietary treatment only, at visit 6 weeks pre‐randomisation any patient having developed symptoms of uncontrolled diabetes or who had fasting plasma glucose of &gt;13 mmol/L was withdrawn and commenced or recommenced on oral antihyperglycaemic agents <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> overweight, diet‐controlled patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> type 2 diabetes, 45‐80 years; diet‐treated with an HbA1c &lt;7.0% or low‐dose oral hypoglycaemic therapy with HbA1c &lt;7.5%; BMI &gt;27kg/m2; women of childbearing age had to be sterilised or use a reliable contraceptive <br> EXCLUSION CRITERIA: <br> diet‐treated with an HbA1c &gt;10%; currently taking lipid‐lowering therapy; previously intolerant of any study medications; study medications would be contraindicated (alanine transaminase more than three times the upper limit of normal, serum creatinine &gt;150 µmol/L, history of heart failure); recent myocardial infarction (&lt;3 months); uncontrolled angina; uncontrolled hypertension <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> treated hypertension: <br> ‐ intervention 40%; <br> ‐ control 1 60%; <br> ‐ control 2 65%; <br> ‐ one current smoker in each group. <br> CO‐MEDICATIONS: <br> treated with aspirin: <br> ‐ intervention 15%; <br> ‐ control 1 30%; <br> ‐ control 2 20%. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> one <br> COUNTRY/ LOCATION: <br> UK <br> SETTING: <br> unclear <br> INTERVENTION 1 (DOSE/DAY): <br> pioglitazone; 30 mg once a day (up to 45 mg o.d.) <br> CONTROL 1 (DOSE/DAY): <br> metformin; 500 mg twice a day (up to 1g t.i.d) <br> CONTROL 2 (DOSE/DAY): <br> gliclazide; 80 mg once a day (up to 160 mg b.d.) <br> TREATMENT BEFORE STUDY: <br> 12‐15 in each group previously on oral antihyperglycaemic agents; 8‐12 in each group treated hypertension; 3‐6 in each group treated with aspirin <br> TITRATION: <br> if fasting blood glucose remained &gt;7 mmol/L treatment was uptitrated to a maximum of metformin 1g t.i.d., pioglitazone 45 mg o.d., or gliclazide 160 mg b.d. (for three months, then kept fixed for a further three months) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> lipoprotein subfractions; sample size calculation based on triglycerides <br> SECONDARY OUTCOMES: <br> HbA1c, renal function, liver function, glucose, full blood count </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the effects of metformin, pioglitazone, and gliclazide on lipoprotein subfractions in overweight, diet‐controlled type 2 diabetic patients </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Matthews 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 52 weeks <br> DURATION OF FOLLOW‐UP: <br> 52 weeks <br> RUN‐IN PERIOD: <br> none, but dietary advice given with the aim of body weight normalisation <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus inadequately controlled with metformin alone <br> INCLUSION CRITERIA: <br> type 2 diabetes inadequately managed with metformin alone (at &gt;=50% of max recommended dose or at max tolerated dose for &gt;=3 months); age 35 and 75 years; HbA1c &gt;=7.5% or &lt;=11.0%; fasting C‐peptide of &gt;=1.5 ng/ml, stable or worsening glycaemic control for &gt;=3 months prior to screening <br> EXCLUSION CRITERIA: <br> type 1 diabetes, ketoacidosis, myocardial infarction, transient ischaemic attacks or stroke in previous 6 months, symptomatic heart failure, acute malabsorption or chronic pancreatitis, familial polyposis coli, malignant disease in the previous 10 years or substance abuse; female patients had to be postmenopausal, sterilised or using adequate contraception; pregnant or breastfeeding excluded; previous treatment with insulin, gliclazide, pioglitazone or other sulphonylureas or TZDs not permitted <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> during study, thiazides permitted to treat oedema; if antihypertensive treatment was indicated, ACE inhibitors, angiotensin II receptor antagonists or calcium antagonists were given </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 75 <br> COUNTRY/ LOCATION: <br> nine European countries, Australia <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 15 mg once a day, up to 45 mg once a day (70% of patients up to maximum dose, mean daily dose 39 mg); plus metformin at pre‐study dose <br> CONTROL (DOSE/DAY): <br> gliclazide; 80 mg once a day, up to 160 mg twice a day (33% of patients up to maximum dose, mean daily dose 212 mg); plus metformin at pre‐study dose <br> TREATMENT BEFORE STUDY: <br> ‐ intervention: mean metformin dose 1726 mg/day (500‐3000 mg/day); <br> ‐ control: mean metformin dose 1705 mg/day (500‐3000 mg/day). <br> TITRATION: <br> 16 weeks forced dose titration, pioglitazone titrated from 15 mg once daily to 30 and 45 mg; gliclazide from 80 mg once daily to 160 mg, 240 mg (160 and 80 mg), and 320 mg (160 mg twice a day); cessation of titration only permitted on the basis of tolerability issues, including actual hypoglycaemia or risk of hypoglycaemia; dose achieved at week 16 was maintained for remaining 36 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> change in HbA1c from baseline to week 52 <br> SECONDARY OUTCOMES: <br> FPG, insulin, lipids, C‐peptide, 32,33 split pro‐insulin, urinary albumin and creatinine, adverse events, laboratory tests, clinical examination </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to assess the long‐term efficacy, safety and tolerability of add‐on therapy of pioglitazone, compared with addition of sulphonylurea (gliclazide), to continued metformin in patients with type 2 diabetes inadequately controlled with metformin alone. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Mattoo 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 6 months <br> DURATION OF FOLLOW‐UP: <br> 6 months <br> RUN‐IN PERIOD: <br> up to 14 days: patients remained on their prescribed insulin therapy regimen (insulin monotherapy or insulin plus oral antidiabetic medication) <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus on insulin therapy <br> INCLUSION CRITERIA: <br> type 2 diabetes according to WHO criteria; used insulin therapy (with or without an oral antihyperglycaemic medication) for &gt;= 3 months; had an HbA1c value &gt;= 7.5% at screening and were &gt;= 30 years old at the time of diabetes diagnosis <br> EXCLUSION CRITERIA: <br> type 1 diabetes; clinical signs or symptoms of any chronic systemic condition (liver disease, diminished cardiac function, renal impairment, transplantation or dialysis, HIV infection), or sign or symptoms of drug or alcohol abuse; previous thizolidinedione use, systemic glucocorticoid therapy, nicotinic acid at a dose &gt; 500 mg/d, or therapy for malignancy other than basal cell or squamous cell skin cancer; women who were breastfeeding or pregnant, as well as women of childbearing potential who were not actively practicing birth control <br> DIAGNOSTIC CRITERIA: <br> WHO 1999 <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> patients were allowed to use any concomitant medication required, except another oral antidiabetic medication, systemic glucocorticoid therapy, or nicotinic acid (&gt; 500 mg/d) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> multi, not stated <br> COUNTRY/ LOCATION: <br> not stated, multinational <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 30 mg/day + insulin <br> CONTROL (DOSE/DAY): <br> placebo + insulin <br> TREATMENT BEFORE STUDY: <br> ‐ all patients received diabetes education, including dietary and exercise guidelines, and were instructed to maintain their individual diet and exercise regimens throughout the study; <br> ‐ patients were instructed on self‐monitoring of blood glucose; <br> ‐ if the patients were using insulin plus oral antidiabetic medication combination therapy, the oral antidiabetic medication was taken unchanged until the day before visit 2 (insulin intensification period of three months between visit 2 and visit 6, see below), at which point it was stopped. <br> TITRATION: <br> ‐ all patients went through a 3‐month insulin intensification period; <br> ‐ the intent of this intensification was to exclude patients, who could obtain glycaemic control (i.e. attain an HbA1c value &lt; 7.0%) with insulin alone; ‐ patients with HbA1c values &gt;= 7.0% after insulin intensification were randomised. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> change in HbA1c from baseline (sample size calculation) <br> SECONDARY OUTCOMES: <br> adverse events including hypoglycaemic episodes, safety parameters, body weight, FPG, serum lipids, free fatty acids, highly sensitive CRP, plasminogen activator inhibitor‐1 (PAI‐1) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to test the hypothesis that adding pioglitazone 30 mg (compared to placebo) would further improve the glycaemic control of patients on insulin therapy who still had an HbA1c value &gt; 7%. The effect of pioglitazone plus insulin on the serum lipid profile and selected cardiovascular risk factors in these patients was also studied </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Adequate</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Pavo 2003 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 32 weeks <br> DURATION OF FOLLOW‐UP: <br> 32 weeks <br> RUN‐IN PERIOD: <br> single‐blind run‐in phase (3‐5 weeks), one placebo tablet and three placebo capsules <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> pharmaco‐naive patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> patients with recently diagnosed type 2 diabetes (&lt;12 months), defined by WHO criteria, HbA1c 7.5‐11.0%; &gt;=40 years <br> EXCLUSION CRITERIA: <br> history of lactic acidosis, liver disease, NYHA cardiac status class III or IV congestive heart failure, HIV infection, renal transplant, impaired kidney function, impaired liver function (defined), BMI below 20 kg/m2 or above 40 kg/m2, breastfeeding, pregnant, or of childbearing potential, participation in any clinical trial that included any drugs; undergoing therapy with nicotinic acid, renal dialysis or cancer therapy; anaemia; systemic glucocorticoid therapy or use of OAM, ACE inhibitors, or angiotensin II receptor agonists within 30 days; known allergy to metformin or any TZD drug <br> DIAGNOSTIC CRITERIA: <br> WHO 1999 <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 19 <br> COUNTRY/ LOCATION: <br> Russia (4 sites), Hungary (15 sites) <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 30 mg/day, titrated to max of 45 mg/day, mean dose 41.5 mg/day <br> CONTROL (DOSE/DAY): <br> metformin; 850 mg/day, titrated to max of 2550 mg/day, mean dose 2292 mg/day <br> TREATMENT BEFORE STUDY: <br> patients received diabetes education and individualised dietary and physical activity instructions (run‐in) <br> TITRATION: <br> ‐ intervention: after randomisation, one 30 mg pioglitazone capsule and 3 placebo tablets daily, after 8 weeks, if FGP &gt;= 7mmol/L, pioglitazone increased to 45mg capsule (+3 placebo tablets) (77% of group); <br> ‐ control: after randomisation, one placebo capsule, one 850mg metformin tablet, 2 placebo tablets identical to metformin tablet daily; then 2 weeks post‐randomisation dose increased to two 850mg tablets (1700mg) +1 placebo tablet +1 placebo capsule; after 8 weeks, if FGP &gt;=7mmol/L, metformin increased to three 850mg tablets (2550mg) +1 placebo capsule (73% of group). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> change in HbA1c <br> SECONDARY OUTCOMES: <br> insulin sensitivity (HOMA‐S), lipoproteins, safety (BP, heart rate, weight, routine blood laboratory parameters, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the efficacy and tolerability of monotherapy with pioglitazone to metformin in recently diagnosed type 2 diabetes patients (naive to oral antihyperglycaemic medication). <br> the primary objective was to compare the effect of each treatment on glycaemic control (change in HbA1c) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Scherbaum 2002 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 26 weeks <br> DURATION OF FOLLOW‐UP: <br> 26 weeks <br> RUN‐IN PERIOD: <br> 10 week placebo washout period (at the end, HbA1c had to remain between 7.5 and 12% and FPG between 140 and 250 mg/dl) ‐ discontinuationof previous oral antidiabetic therapy <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> patients with type 2 diabetes mellitus, phase II study <br> INCLUSION CRITERIA: <br> type 2 diabetes, 35 to 70 years, BMI 25‐35 kg/m2 at screening, HbA1c 7.5‐12%, FPG 140‐300 mg/dl (=250 mg/dl at end of washout period); female participants had to be postmenopausal, surgically sterilised, or using appropriate contraception <br> EXCLUSION CRITERIA: <br> type 1 diabetes, secondary failure to treatment with sulphonylureas, requirement for other antidiabetic treatment; history of ketoacidosis, malabsorption, acute or chronic pancreatitis, liver disease, significant ventricular hypertrophy, complex cardiac arrhythmias, angina pectoris, heart failure, myocardial infarction, hypertension (defined), stroke, hypothyroidism, history of transient ischaemic attack or stroke, significant anaemia of any aetiology, clinically relevant haematological or malignant disease in the last 10 years, HIV infection, alcohol or drug abuse, participation in clinical trial in 3 months prior to study <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 59 <br> COUNTRY/ LOCATION: <br> Germany <br> SETTING: <br> unclear <br> INTERVENTION 1 (DOSE/DAY): <br> pioglitazone; 15 mg/day (once daily) <br> INTERVENTION 2 (DOSE/DAY): <br> pioglitazone; 30 mg/day (once daily) <br> CONTROL (DOSE/DAY): <br> matching placebo <br> TREATMENT BEFORE STUDY: <br> 61% previous antidiabetic treatment, most commonly (13%) acarbose and (17%) glibenclamide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> change in HbA1c from baseline to final visit <br> SECONDARY OUTCOMES: <br> blood glucose, C‐peptide, blood pressure, plama lipids, body weight, adverse events (incl. hypoglycaemia) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the efficacy and tolerability of pioglitazone 15 mg/day and 30 mg/day monotherapy to placebo in European patients with type 2 diabetes (in addition to dietary control) </p> <p>phase II study</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Schernthaner 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: 52 weeks DURATION OF FOLLOW‐UP: 52 weeks RUN‐IN PERIOD: none LANGUAGE OF PUBLICATION: English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> pharmaco‐naive patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> 35‐75 years, type 2 diabetes inadequately treated with diet alone, HbA1c 7.5‐11% with stable or worsening glycaemia for at least 3 months; corticosteroids and beta‐blockers permitted if treatment commenced at least 4 weeks before screening; antihypertensive agents ‐ except thiazides ‐ allowed dependent on clinical need; lipid‐lowering agents also permitted <br> EXCLUSION CRITERIA: <br> prior use of glucose‐lowering pharmacotherapy, specific contraindications to either drug <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> ‐ Intervention: ACE inhibitors 31%, 11% lipid lowering therapy; <br> ‐ control: ACE inhibitors 29%, 10% lipid lowering therapy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 167 <br> COUNTRY/ LOCATION: <br> 12 European countries <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; up to 45 mg/day (14.1% on 30 mg/day, 85.9% on 45 mg/day; mean dose 43 mg/day) <br> CONTROL (DOSE/DAY): <br> metformin; up to 850 mg three times daily (2550 mg/day) (11.8% on 850 mg/day, 26.5% on 1700 mg/day, 61.6% on 2550 mg/day; mean dose 2124 mg/day) <br> TREATMENT BEFORE STUDY: <br> both groups: instructed to adhere to disease‐ and weight‐oriented diet throughout the study; dietary advice given at baseline with aim of body weight normalisation; if body weight increased any more than 5% at any stage or HbA1c increased to greater than 9% after completed dose titration, patients were given additional intensive dietary counselling <br> TITRATION: <br> 12 week forced dose titration: <br> ‐ intervention: starting on 30mg/day of pioglitazone, up to 45 mg/day (with metformin placebo); <br> ‐ control: starting on 850mg of metformin once daily, up to three times daily (2550 mg/day) (with pioglitazone placebo); <br> ‐ dose levels increased, maintained or decreased at weeks 4, 8 and 12 according to tolerability; dose reached at week 12 fixed for remainder of study. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: HbA1c SECONDARY OUTCOMES: FPG, insulin, lipid profiles, adverse events, laboratory tests, at selected centres: C‐peptide and proinsulin and standard oral glucose tolerance test </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the effects of pioglitazone with metformin on metabolic variables in type 2 diabetes patients naive to oral hypoglycaemic therapy; to determine any additional benefits on lipid profiles, hyperinsulinaemia, and glucose disposal during oral glucose tolerance tests </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Adequate</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Smith 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 24 weeks <br> DURATION OF FOLLOW‐UP: <br> 24 weeks <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> mainly white patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> 35 to 75 years, type 2 diabetes (defined as FPG of 126 mg/dl or higher at entry or FPG of more than 115 mg/dl and a 2h oral glucose tolerance test of 200 mg/dl or higher); FPG at entry had to be 200 mg/dl or less; for women adequate contraceptive control required (defined); patients could be treated with diet, metformin or sulphonylurea (continued as necessary throughout the study) <br> EXCLUSION CRITERIA: <br> significant renal, cardiac, liver, lung or neurological disease; controlled hypertension acceptable if baseline blood pressure was less than 140/90 mmHg on medications; patients with prior use of TZDs, beta‐blockers, current pregnancy, smokers, alcohol or other drug abusers, or unwilling to abstain from caffeine for 48 hours and alcohol for 24 hours prior to metabolic rate measurements; metal objects that would interfere with measurement of visceral fat with CT (e.g. implanted rods, surgical clips) prevented people from participating; also excluded: patients taking drugs known to affect lipid metabolism, energy metabolism or body weight, e.g. orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosteroids <br> DIAGNOSTIC CRITERIA: <br> FPG of 126 mg/dl or higher at entry or FPG of more than 115 mg/dl and a 2h oral glucose tolerance test of 200 mg/dl or higher <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> some took sulphonylureas (placebo group 9/21, pioglitazone 11/21), some metformin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> one <br> COUNTRY/ LOCATION: <br> USA <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 30 mg/day <br> CONTROL (DOSE/DAY): <br> placebo <br> TREATMENT BEFORE STUDY: <br> sulphonylurea or metformin continued as necessary (if taken before). <br> instructions on a healthy diet for diabetic patients by a dietitian. <br> TITRATION: <br> HbA1c target was 7.0% or less; if after 8 weeks, the HbA1c level was 7% or greater or FPG was 100 mg/dl or greater, dosage of pioglitazone (or matching placebo) increased to 45 mg/day (all but one patient); patients on sulphonylureas or metformin experiencing hypoglycaemia had the dose of these medications reduced or the medication discontinued </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> not stated (visceral, subcutaneous and total body fat) <br> SECONDARY OUTCOMES: <br> HbA1c, insulin, glucose, insulin resistance (QUICKI), triglycerides, HDL, LDL and total cholesterol, weight, BMI, subjective measures for hunger and fullness (visual analogue scale), resting metabolic rate, change of metabolic rate after a meal; body composition </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> primary aim to evaluate the effect of TZDs on visceral, subcutaneous and total body fat; secondary aims to determine effects of pioglitazone on a) energy expenditure, b) hunger and satiety, c) blood lipids, d) the role of insulin/sulphonylurea usage on weight gain in patients with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Tan 2004a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 52 weeks <br> DURATION OF FOLLOW‐UP: <br> 52 weeks <br> RUN‐IN PERIOD: <br> 1‐3 weeks, patients received diaries for recording self‐monitored blood glucose and hypoglycaemic events; diabetes education and diet and exercise instructions; patients currently on anthyperglycaemic monotherapy continued this until day 1 of titration period <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> Mexican patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> type 2 diabetes, HbA1c &gt;7.5 to &lt;=11% in patients not receiving oral antihyperglycaemic agent monotherapy, and &gt;7.5 to &lt;=9.5% in patients receiving oral antihyperglycaemic agent monotherapy; eligible patients must have undergone an adequate trial of dietary and lifestyle interventions before enrollment <br> EXCLUSION CRITERIA: <br> treatment with TZD or insulin within previous 3 months; current prescription of maximum dose of oral antihyperglycaemic agent or for combination therapy; treatment with systemic glucocorticoids (incl. topical and inhaled) within previous 30 days; cardiac disease with substantial limitation of functional capacity (NYHA class III or IV); serum triglycerides &gt;400mg/dl, serum creatinine &gt;2.0mg/dl, renal transplantation or current renal dialysis; ALT or AST &gt;2.5 times upper limit of normal; clinical signs or symptoms of liver disease; haemoglobin &lt;105 g/L for women or &lt;115 g/L for men; previous HIV infection, signs and symptoms of substance abuse <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> ‐ intervention: antilipidaemic agents (fibrates, statins, or both) 12.4%; <br> ‐ control: antilipidaemic agents (fibrates, statins, or both) 11.4%. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 19 <br> COUNTRY/ LOCATION: <br> Mexico <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; 15 mg up to 45 mg q.d.; mean final dose 37 mg q.d. <br> CONTROL (DOSE/DAY): <br> glimepiride; 2 mg up to 8 mg q.d., mean final dose 6 mg q.d. <br> TREATMENT BEFORE STUDY: <br> ‐ intervention: 76% receiving oral antihyperglycaemic agent (52.1% secretagogues, 22.3% metformin), antilipidaemic agents (fibrates, statins, or both) 12.4%; <br> ‐ control: 77.2% receiving oral antihyperglycaemic agent (57.7% secretagogues, 19.5% metformin), antilipidaemic agents (fibrates, statins, or both) 11.4%; <br> ‐ all patients received diabetes education and diet and exercise instructions. <br> TITRATION: <br> 12 weeks, initial dose pioglitazone 15 mg q.d. and glimepiride 2 mg q.d.; goal of titration to achieve FPG &lt;=7 mmol/l and 1h postprandial blood glucose &lt;=10 mmol/l; if FPG or post‐prandial blood glucose concentrations were consistently higher than glycaemic target, dose adjustments were made at 4 week intervals (through week 12 of titration period); pioglitazone: 15mg increments up to max of 45 mg q.d.; glimepiride 2mg increments up to max of 8 mg q.d.; investigators encouraged to keep doses constant thereafter </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> insulin sensitivity (HOMA, QUICKI, fasting insulin concentrations) <br> SECONDARY OUTCOMES: <br> HbA1c; lipids, lipoproteins, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the effectiveness of 52 weeks treatment with pioglitazone and glimepiride in providing long term glycaemic control and increasing insulin sensitivity in Mexican patients with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Adequate</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Tan 2004b </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 52 weeks <br> DURATION OF FOLLOW‐UP: <br> 52 weeks <br> RUN‐IN PERIOD: <br> 1‐3 week washout period (OAD); instructions to maintain current diet and exercise regimen throughout study; diaries for recording self‐monitored blood glucose measurements and hypoglycaemic events <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> Scandinavian patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> type 2 diabetes, naive to oral antidiabetics or monotherapy; HbA1c &gt;7.5% to &lt;=11% for patients not receiving oral antidiabetics or &gt;7.5% and &lt;=9.5% for patients receiving monotherapy; fasting C‐peptide of 0.333 pmol/L (1 ng/ml) at screening; had received adequate trial of dietary or lifestyle intervention <br> EXCLUSION CRITERIA: <br> insulin treatment within 30 days prior to screening; glucocorticoid therapy (excluding topical or inhaled preparations) within 4 weeks of screening; currently on maximum dose of one oral antihyperglycaemic or on combination therapy; cardiac disease with substantial limitation of functional capacity (NYHA class III or IV cardiac status); serum creatinine &gt;177 µmol/L; renal transplant or current renal dialysis; ALT or AST &gt;2.5 times the upper limit of normal; clinical signs or symptoms of liver disease, haemoglobin or haematocrit below the lower limit of normal <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> lipoprotein‐altering medication at screening: <br> ‐ control: 26%; <br> ‐ intervention: 32%. <br> antihypertensives at sceening: <br> ‐ control: 43%; <br> ‐ intervention: 50%. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> 22 <br> COUNTRY/ LOCATION: <br> Denmark, Finland, Norway, Sweden <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone; from 30 mg/day to 45 mg/day <br> CONTROL (DOSE/DAY): <br> micronized glibenclamide; from 1.75 mg/day to max 10.5 mg/day <br> TREATMENT BEFORE STUDY: <br> ‐ control: 69% oral antidiabetics at screening (55% SU, 44% metformin, one patient repaglinide); <br> ‐ intervention: 70% oral antidiabetics at screening (58% SU, 42% metformin); <br> ‐ during the washout period patients received instructions to maintain current diet and exercise regimen throughout the study. <br> TITRATION: <br> 12 week titration period; glibenclamide initial dose 1.75 mg, pioglitazone initial dose 30 mg; titration goal to achieve FBG of &lt;=7mmol/L and 1h postprandial glucose of &lt;=10 mmol/L; dose of medication adjusted if FBG or postprandial glucose consistently higher than the titration goal; for pioglitazone, dose increased to 45 mg/day, for glibenclamide increased to 3.5 mg/day at week 4, to 7.0 mg/day at week 8, and to 10.5 mg at week 12; dose adjustments for optimal control allowed during maintenance period <br> intervention: 75% received maximal dose allowed (45 mg); control: 62% received maximal dose allowed (10.5 mg) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> HOMA insulin sensitivity (used for power calculation) <br> SECONDARY OUTCOMES: <br> HbA1c, FPG, fasting serum insulin, lipids, safety assessments incl. adverse event recording </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare the effect of 52 weeks' treatment with micronized glibenclamide and pioglitazone on indicators of insulin sensitivity, glycaemic control, serum lipids and safety or tolerability in type 2 diabetic patients who were either naïve to oral antihyperglycaemic medication or had previously received oral monotherapy </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Watanabe 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 6 months <br> DURATION OF FOLLOW‐UP: <br> 6 months <br> RUN‐IN PERIOD: <br> none <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> untreated Japanese patients with type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> untreated type 2 diabetes patients according to criteria of the Japanese Diabetes Society (FPG &gt; 126 mg/dl), HbA1c 6.5‐8.0% <br> EXCLUSION CRITERIA: <br> kidney disease <br> DIAGNOSTIC CRITERIA: <br> criteria of the Japanese Diabetes Society (FPG &gt; 126 mg/dl), HbA1c 6.5‐8.0% <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> ‐ patients were forbidden to change dosing schedule of drugs they were receiving in addition to study drugs; <br> ‐ intervention (individuals): Ca antagonist 8, ACE inhibitor 8, statins 13, beta‐blocker 3; <br> ‐ control (individuals): Ca antagonist 10, ACE inhibitor 11, statins 14, beta‐blocker 3. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> one <br> COUNTRY/ LOCATION: <br> Japan <br> SETTING: <br> unclear <br> INTERVENTION (DOSE/DAY): <br> pioglitazone, started at 15 mg/day, mean dose 17.3 mg/day <br> CONTROL (DOSE/DAY): <br> glibenclamide, 1.25‐2.5 mg/day (mean dose 1.56 mg/day) <br> TREATMENT BEFORE STUDY: <br> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> not stated (pulse wave velocity) <br> SECONDARY OUTCOMES: <br> BMI, blood pressure, HbA1c, brachial ankle pulse wave velocity, FPG, fasting immunoreactive insulin, HOMA: insulin resistance, lipid parameters </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to investigate the anti‐arteriosclerotic effects of pioglitazone in patients with diabetes mellitus using pulse wave velocity as an index of efficacy </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Yamanouchi 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DURATION OF INTERVENTION: <br> 12 months <br> DURATION OF FOLLOW‐UP: <br> 12 months <br> RUN‐IN PERIOD: <br> one month for baseline measurements <br> LANGUAGE OF PUBLICATION: <br> English </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>WHO PARTCIPATED: <br> drug‐naive Japanese patients with a short duration of type 2 diabetes mellitus <br> INCLUSION CRITERIA: <br> patients continued in the study if they met the inclusion criteria of HbA1c &gt;= 7.0% and FPG &gt;= 7.78 mmol/ l, at the end of the 1‐month observation period; all patients had a body mass index (BMI) between 22 and 35 kg/m2 (mean 25.9 kg/m2); the criteria for obesity in Japanese people are BMI <br> = 25 kg/m2 <br> EXCLUSION CRITERIA: <br> patients who had unstable or rapidly progressive diabetic retinopathy, nephropathy, or neuropathy; patients with liver dysfunction (AST, ALT &gt; 1.5× upper limit of normal); impaired kidney function (serum creatinine &gt; 133µmol/l), or anaemia; patients with a myocardial infarction, angina, congestive heart failure, or a documented cerebrovascular accident <br> DIAGNOSTIC CRITERIA: <br> not stated <br> CO‐MORBIDITIES: <br> not stated <br> CO‐MEDICATIONS: <br> ‐ antihypertensive drugs or other concurrent treatments, including dietary regimens, remained unchanged throughout the study; <br> ‐ the number of patients taking antihypertensive medications were 16 (42%), 18 (46%) and 18 (49%) (for the pioglitazone, metformin and glimepiride groups, respectively); <br> ‐ none of the participiants was on lipid‐lowering therapy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>NUMBER OF STUDY CENTRES: <br> not stated <br> COUNTRY/ LOCATION: <br> Japan <br> SETTING: <br> unclear <br> INTERVENTION 1 (DOSE/DAY): <br> pioglitazone; 30‐45 mg/day <br> CONTROL 1 (DOSE/DAY): <br> metformin; 750 mg/day <br> CONTROL 2 (DOSE/DAY): <br> glimepiride; 1.0‐2.0 mg/day <br> TREATMENT BEFORE STUDY: <br> ‐ no patient had ever received an oral hypoglycaemic agent or a lipid drug; <br> ‐ all patients were treated with diet and exercise alone for at least 3 months, including the 1 month for baseline measurements before the study (observation period). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>PRIMARY OUTCOMES: <br> HbA1c <br> SECONDARY OUTCOMES: <br> FPG, 1,5‐anhydroglucitol, plasma insulin, haematology, biochemistry, adverse events, BMI, blood pressure, lipids, free fatt acids </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>AIM OF STUDY: <br> to compare changes in major metabolites for 12 months when TZD, biguanide, or glimepiride were used in drug‐naive Japanese patients with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment?</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>B ‐ Unclear</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACE = ; ADA = American Diabetes Association; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ATII or AT2 = ; b.d. = bis in die, twice daily; BMI = body mass index (kg(m2); BP = blood pressure; CRP = C‐reactive protein; CVD = cardiovascular disease; FPG = fasting plasma glucose; HbA1c = glycosylated haemoglobin A1c; HOMA = homeostasis model assessment (of insulin sensitvity); NYHA = New York Heart Association; OAM = oral antidiabetic medication; o.d. = once daily; PPAR = peroxisome proliferator activated receptor; q.d. = quaque die, once a day; QUICKI = quantitative insulin sensitivity check index; SU = sulfonylureas; t.i.d. = ter in die, three times daily; TZD = thiazolidinediones ("glitazones"); WHO = World Health Organisation </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD006060-sec2-0034"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006060-sec2-0033" class="jump-to">included studies</a></li> <li><a href="#CD006060-sec2-0035" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0023">Koshiyama 2001</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>not a randomised controlled clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0024">Nagashima 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>treatment duration less than 24 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0025">Nishio 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>randomised controlled trial, but no placebo or other intervention in the control group</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0026">Roberts 2005b</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>glimepiride versus "thiazolidinediones", no data on pioglitazone available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0027">Schofl 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>treatment duration less than 24 weeks, observational study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0028">Takagi 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>conventional anti‐diabetic treatment versus "thiazolidinedione treatment", no data on pioglitazone available </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006060-bbs2-0029">Tseng 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>treatment duration less than 24 weeks</p> </td> </tr> </tbody> </table> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD006060-sec2-0035"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006060-sec2-0033" class="jump-to">included studies</a></li> <li><a href="#CD006060-sec2-0034" class="jump-to">excluded studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ACCORD </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Action to Control Cardiovascular Risk in Diabetes (ACCORD)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All 10,251 participants will be in the overarching glycemia trial. In addition, one 2 X 2 trial will also address the lipid question in 5,518 of the participants and the other 2 X 2 trial will address the blood pressure question in 4,733 of the participants. </p> <p>The three specific primary ACCORD hypotheses are as follow. In middle‐aged or older people with type 2 diabetes who are at high risk for having a cardiovascular disease (CVD) event because of existing clinical or subclinical CVD or CVD risk factors: <br> 1. does a therapeutic strategy that targets a HbA1c of &lt; 6.0% reduce the rate of CVD events more than a strategy that targets a HbA1c of 7.0% to 7.9% (with the expectation of achieving a median level of 7.5%)? <br> 2. in the context of good glycemic control, does a therapeutic strategy that uses a fibrate to raise HDL‐C/lower triglyceride levels and uses a statin for treatment of LDL‐C reduce the rate of CVD events compared to a strategy that only uses a statin for treatment of LDL‐C? <br> 3. In the context of good glycemic control, does a therapeutic strategy that targets a systolic blood pressure (SBP) of &lt; 120 mm Hg reduce the rate of CVD events compared to a strategy that targets a SBP of &lt; 140 mm Hg? </p> <p>The 10,251 participants will be treated and followed for about 4 to 8 years (approximate mean of 5.6 years) at 77 Clinical Sites administratively located within 7 Clinical Center Networks in the United States and Canada. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The design is a randomized, multicenter, double 2 X 2 factorial design in 10,251 patients with type 2 diabetes mellitus. The trial is designed to test the effects on major CVD events of intensive glycemia control, of treatment to increase HDL‐cholesterol and lower triglycerides (in the context of good LDL‐C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary outcome measure for the trial is the first occurrence of a major cardiovascular disease event, specifically nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. </p> <p>The ACCORD study is designed to have: <br> * 89% power to detect a 15% treatment effect of intensive glycemic control compared with standard glycemic control, <br> * 87% power to detect a 20% treatment effect of lipid control through LDL‐C treatment and fibrates compared with lipid control using LDL‐C treatment alone, <br> * 94% power to detect a 20% treatment effect of intensive blood pressure control compared with standard blood pressure control. </p> <p>Secondary hypotheses include treatment differences in other cardiovascular outcomes, total mortality, microvascular outcomes, health‐related quality of life, and cost‐effectiveness. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Recruitment occurred in two non‐contiguous periods: an initial period that began in January 2001 for the Vanguard Phase of the trial (during which 1174 participants were randomized) and then a subsequent period beginning in January 2003 and ending in October 2005. </p> <p>Follow‐up is scheduled to end in June 2009, with the primary results announced in early 2010. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ACCORD is sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI Project Office is responsible for the administration and monitoring of the trial. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Despite the importance of this health problem in the North American population, there is a lack of definitive data on the effects of intensive control of glycemia and other CVD risk factors on CVD event rates in diabetic patients. </p> <p>The overall goal of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is to address this challenge by testing three complementary medical treatment strategies for type 2 diabetes to enhance the options for reducing the still very high rate of major CVD morbidity and mortality in this disease. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">BARI‐2D </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Eligibility ‐ <br> Genders Eligible for Study: Both Criteria </p> <p>Inclusion Criteria for BARI 2D <br> 1. Diagnosis of Type 2 diabetes mellitus. <br> 2. Coronary arteriogram showing one or more vessels amenable to revascularization (=50% stenosis). <br> 3. Objective documentation of ischemia OR subjectively documented typical angina with =70% stenosis in at least one artery. <br> 4. Suitability for coronary revascularization by at least one of the available methods (does not require the ability to achieve complete revascularization). <br> 5. Ability to perform all tasks related to glycemic control and risk factor management. <br> 6. Age 25 or older. <br> 7. Informed written consent. </p> <p>Exclusion Criteria for BARI 2D <br> 1. Definite need for invasive intervention as determined by the attending cardiologist. <br> 2. Prior bypass surgery (CABG) or prior catheter‐based intervention within the past 12 months. <br> 3. Planned intervention for disease in bypass graft(s) if the patient is randomized to a strategy of initial revascularization. <br> 4. Class III or IV CHF. <br> 5. Creatinine &gt; 2.0 mg/dl. <br> 6. HbA1c &gt; 13%. <br> 7. Need for major vascular surgery concomitant with revascularization (e.g., carotid endarterectomy). <br> 8. Left main stenosis &gt; 50%. <br> 9. Non‐cardiac illness expected to limit survival. <br> 10. Hepatic disease (ALT&gt; 2 times the ULN). <br> 11. Fasting triglycerides &gt; 1000 mg/dl in the presence of moderate glycemic control (HbA1c &lt;9.0%). <br> 12. Current alcohol abuse. <br> 13. Chronic steroid use judged to interfere with the control of diabetes, exceeding 10 mg. of Prednisone per day or the equivalent. <br> 14. Pregnancy, known, suspected, or planned in next 5 years. <br> 15. Geographically inaccessible or unable to return for follow‐up. <br> 16. Enrolled in a competing randomized trial or clinical study. <br> 17. Unable to understand or cooperate with protocol requirements. </p> <p>Patients with Type 2 diabetes mellitus and CAD documented by coronary arteriography will be eligible for the trial if revascularization is not required for prompt control of severe or unstable angina. Diabetic patients who are being treated with insulin or oral hypoglycemic drugs will be eligible as well as diabetic patients treated with diet and exercise alone provided that a diagnosis of diabetes can be confirmed by record review or that a fasting plasma glucose (FPG)&gt;125/mg/dl (7.0 mmol/l) can be obtained. The determination of suitability for BARI 2D will be made by a physician‐investigator at each participating institution on clinical grounds at the time of coronary angiography. </p> <p>Significant CAD will be defined as at least one stenosis &gt;50%. Angina and ischemia will be assessed by use of patient self‐report, physician examination, and appropriate diagnostic measures including exercise myocardial perfusion imaging, exercise echocardiography, and IV dipyridamole or adenosine myocardial perfusion imaging or invasively by doppler or pressure wire. Objective documentation of myocardial ischemia includes any of the following: <br> 1. Exercise or pharmacologically‐induced: <br> 1. =1 mm of horizontal or downsloping ST depression or elevation for =60‐80 milliseconds after the end of the QRS complex; <br> 2. myocardial perfusion defect; <br> 3. myocardial wall motion abnormality. <br> 2. Stabilized, prior acute coronary syndrome with CK‐MB or troponin elevation or with new, =0.5 mm ST depression or elevation, or T wave inversion of =3 mm in 2 contiguous ECG leads. <br> 3. Doppler or pressure wire showing coronary flow reserve (CFR) &lt;2.0 or fractional flow reserve (FFR) &lt;0.75. </p> <p>Among patients without documented ischemia, only patients with stenosis = 70% presenting with classic anginal symptoms will be eligible for randomization. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study Type: Interventional <br> Study Design: Treatment, Randomized, Factorial Assignment </p> <p>A. Primary Aim <br> The primary aim of the BARI 2D trial is to test the following two hypotheses of treatment efficacy in 2800 patients with Type 2 diabetes mellitus and documented stable CAD, in the setting of uniform glycemic control and intensive management of all other risk factors including dyslipidemia, hypertension, smoking, and obesity: <br> 1. Coronary Revascularization Hypothesis: a strategy of initial elective revascularization of choice (surgical or catheter‐based) combined with aggressive medical therapy results in lower 5‐year mortality compared to a strategy of aggressive medical therapy alone; <br> 2. Method of Glycemic Control Hypothesis: with a target HbA1c level of &lt;7.0%, a strategy of hyperglycemia management directed at insulin sensitization results in lower 5‐year mortality compared to a strategy of insulin provision. </p> <p>B. Secondary Aims <br> The secondary aims of the BARI 2D trial include: a) comparing the death, myocardial infarction or stroke combined endpoint event rate between the revascularization versus medical therapy groups and between the insulin sensitization versus insulin provision groups; b) comparing rates of myocardial infarction, other ischemic events, angina and quality of life associated with each revascularization and hyperglycemia management strategy; c) evaluating the relative economic costs associated with the trial treatment strategies, d) exploring the effect of glycemic control strategy on the progression and mechanism of vasculopathy including changes in PAI‐1 gene expression. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary aim of the BARI 2D trial is to test the following two hypotheses of treatment efficacy in 2800 patients with Type 2 diabetes mellitus and documented stable CAD, in the setting of uniform glycemic control and intensive management of all other risk factors including dyslipidemia, hypertension, smoking, and obesity: </p> <p>1. Coronary Revascularization Hypothesis: a strategy of initial elective revascularization of choice (surgical or catheter‐based) combined with aggressive medical therapy results in lower 5‐year mortality compared to a strategy of aggressive medical therapy alone; </p> <p>2. Method of Glycemic Control Hypothesis: with a target HbA1c level of &lt;7.0%, a strategy of hyperglycemia management directed at insulin sensitization results in lower 5‐year mortality compared to a strategy of insulin provision. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study start: September 2000; <br> Study completion: June 2007 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>http://www.bari2d.org/public/contactus.html</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The BARI 2D trial is a multicenter study that uses a 2x2 factorial design, with 2800 patients being assigned at random to initial elective revascularization with aggressive medical therapy or aggressive medical therapy alone with equal probability, and simultaneously being assigned at random to an insulin providing or insulin sensitizing strategy of glycemic control (with a target value for HbA1c of &lt;7.0% for all patients). </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">CHICAGO </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A Study of Pioglitazone HCl Versus Glimepiride in Subjects With Type 2 Diabetes Measuring the Progression of Atherosclerosis (CHICAGO) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study subjects will be treated with either pioglitazone or glimepiride for approximately 72 weeks (18 months). Subjects will make 12 or 13 visits to the study center, 4 visits to the center conducting the carotid ultrasound, and 2 visits to the center conducting the electron beam tomography scan. During visits to the study center, subjects will have blood drawn at each visit, have urine collected at 5 visits, have their vital signs and abdominal and hip girth measured at each visit, have 3 physical exams over the course of the study, and have an ECG at the beginning and end of the study. At each visit, information will be collected regarding adverse events the subject may have experienced and any medications the subject is taking. </p> <p>Eligibility: <br> Ages Eligible for Study: 45 Years ‐ 85 Years, Genders Eligible for Study: Both </p> <p>Inclusion Criteria: <br> ‐ Subjects aged 45 to 85 years, inclusive. <br> ‐ Subjects with type 2 diabetes. <br> ‐ Subjects with HbA1c &gt;6.0% and &lt;9% if taking antidiabetic medications, or HbA1c &gt;6.5% and &lt;10% if not taking antidiabetic medication. </p> <p>Exclusion Criteria: <br> ‐ Subjects with type 1 diabetes, symptomatic CAD, cerebrovascular disease or peripheral vascular disease. <br> ‐ Subjects taking more than two antidiabetic therapies. <br> ‐ Subjects taking thiazolidinediones (TZDs) currently or in the past 12 weeks <br> ‐ Subjects with New York Heart Association Class III or IV cardiac failure or left ventricular dysfunction (left ventricular ejection fraction &lt;40%) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study Design: Treatment, Randomized, Double‐Blind, Active Control, Parallel Assignment, Efficacy Study </p> <p>Study subjects will be treated with either pioglitazone or glimepiride for approximately 72 weeks (18 months). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary Outcomes: Absolute change in carotid intima‐media thickness (CIMT) from baseline to final visit (18 months). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study start: August 2003; <br> Study completion: October 2006 <br> Last follow‐up: April 2006; <br> Data entry closure: July 2006 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Takeda Global Research &amp; Development Center, Inc</p> <p>ClinicalTrials.gov Identifier: NCT00225264</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary purpose of this study is to compare the effects of pioglitazone HCl versus glimepiride on the amount of thickening of the carotid artery, a large vessel in the neck. The carotid artery is measured using a noninvasive procedure called an ultrasound. It is believed that the amount of thickness of the carotid artery can be an indication of the amount of atherosclerosis or heart disease that a person has. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">PERISCOPE </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subjects with type 2 diabetes requiring angiography will have the IVUS procedure performed at baseline and again following 18 months of treatment. Subjects who meet eligibility criteria will be titrated up to a maximum of 45 mg/day pioglitazone HCl or 4 mg/day glimepiride. Subjects will make 11 visits to the study center. During study visits, subjects will have weight, and vital signs assessed as well as abdominal and hip girth. Physical exams will be done at baseline, 12 months, and 18 months. ECG will be done at baseline and 18 months. Lab assessments will be done at each visit. Completed blood count, chemistries, urinalysis and markers of atherosclerosis will be drawn at baseline, and months 6, 12 and 18. At each visit, information will be collected regarding adverse events the subject may have experienced and any medications the subject is taking. Compliance with study medication will also be assessed at each visit. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study Type: Interventional <br> Study Design: Treatment, Randomized, Double‐Blind, Active Control, Parallel Assignment, Efficacy Study </p> <p>Subjects who meet eligibility criteria will be titrated up to a maximum of 45 mg/day pioglitazone HCl or 4 mg/day glimepiride. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary Outcomes: Effect of treatment on the nominal change in percent atheroma volume of the identified target coronary artery segment from baseline after 18 months of treatment as measured by intravascular ultrasound (IVUS) imaging of the coronary arteries. <br> Expected Total Enrollment: 440 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study start: August 2003; <br> Expected completion: March 2008 <br> Last follow‐up: August 2007; <br> Data entry closure: November 2007 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Brigit Isaacson, MT, MBA 847‐383‐3237 <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b9dbd0cad8d8dacad6d7f9cddecbdd97dad6d4">[email&#160;protected]</a></p> <p>ClinicalTrials.gov Identifier: NCT00225277</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary purpose of this study is to compare the effect of pioglitazone HCl versus glimepiride on the coronary atheroma volume using IVUS of the coronary arteries after up to 18 months of treatment. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">PPAR </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pioglitazone Protects DM Patients Against Re‐Infarction (PPAR Study)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Type 2 diabetes mellitus is a well‐established risk factor for coronary heart disease and atherosclerotic change in coronary artery. So we designed a prospective randomized multi‐center trial named the pioglitazone could reduce the recurrence of myocardial infarction in patients with DM and myocardial infarction(PPAR study) to evaluate whether pioglitazone could reduce the recurrence of myocardial infarction in patients with DM(HbA1c&lt;6.5%) and myocardial infarction. </p> <p>100 hospitals will participate in the PPAR study. Patients with DM who have history of prior myocardial infarction are randomly allocated to receive pioglitazone or (1)instructs weight reduction, appropriate diet, regular exercise and/or (2)prescribes sulfonylurea agents. The number of patients to be recruited is 3000 and this study will continue at least 2 years. The primary end‐points are (1) cardiovascular mortality and (2) hospitalization for cardiovascular events. Effects in suppression of new diabetes development also will be evaluated. </p> <p>We should recognize DM as important therapeutic target to decrease recurrence of cardiovascular events. PPAR study, a large scale multi‐center trial in Japan, will provide us new evidence how to treat DM patients with prior myocardial infarction. </p> <p>Eligibility: <br> Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both </p> <p>Inclusion Criteria: <br> 1. diabetes mellitus (HbA1c &lt; 6.5%) <br> 2. History of myocardial infarction </p> <p>Exclusion Criteria: <br> 1. Symptomatic CHF <br> 2. Type I diabetes <br> 3. History of coronary artery bypass graft <br> 4. Severe liver and/or kidney dysfunction <br> 5. History of allergic response to drugs <br> 6. arteriosclerosis obliterans </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study Type: Interventional <br> Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study </p> <p>Patients with DM who have history of prior myocardial infarction are randomly allocated to receive pioglitazone or (1)instructs weight reduction, appropriate diet, regular exercise and/or (2)prescribes sulfonylurea agents. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary Outcomes: 1.Cardiovascular mortality; 2.Hospitalization due to cardiovascular events <br> Secondary Outcomes: (1) All cause mortality; (2) Hospitalization due to coronary artery disease; (3) Progression of IGT to diabetes; (4) Development or deterioration of either hypertension or hyperlipidemia; (5) Deterioraion of renal function; (6) Hospitalization due to cerebrovascular disease; (7) Hospitalization due to heart failure <br> Expected Total Enrollment: 3000 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study start: April 2005; Expected completion: April 2009 <br> Last follow‐up: April 2009; <br> Data entry closure: April 2009 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masafumi Kitakaze, MD, PhD 81‐6‐6833‐5012 Ext. 2225 <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="fd9694899c969c8798bd879bcbd38e92">[email&#160;protected]</a>‐net.ne.jp <br> Jiyoong Kim, MD 81‐6‐6833‐5012 Ext. 8212 <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="5b31323032361b3a2f2f3c3734393a3775353e2f">[email&#160;protected]</a> </p> <p>Japan, OSAKA <br> National Cardiovascular Center, Suita, OSAKA, 565‐8565, Japan; Recruiting <br> Masafumi Kitakaze, MD, PhD 81‐6‐6833‐5012 Ext. 2225 <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e78c8e93868c869d82a79d81d1c99488">[email&#160;protected]</a>‐net.ne.jp </p> <p>Study chairs or principal investigators</p> <p>Masafumi Kitakaze, MD, PhD, Study Chair, National Cardiovascular Center</p> <p>ClinicalTrials.gov Identifier: NCT00212004</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>To evaluate whether the pioglitazone could reduce the recurrence of myocardial infarction in patients with DM and old myocardial infarction </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD006060-sec1-0010"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD006060-tbl-0001"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Adverse events</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 No. of patients experiencing oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11565</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.22 [1.96, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006060-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/ppt/CDSR/CD006060/image_n/nCD006060-CMP-001-01.png?filename=nCD006060-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Adverse%20events%2C%20Outcome%201%20No.%20of%20patients%20experiencing%20oedema.&amp;citation=Richter B, Bandeira%E2%80%90Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, 4. Art. No.: CD006060. DOI: http://dx.doi.org/10.1002/14651858.CD006060.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD006060-fig-00101" src="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/image_n/nCD006060-CMP-001-01.png" alt="Comparison 1 Adverse events, Outcome 1 No. of patients experiencing oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Adverse events, Outcome 1 No. of patients experiencing oedema.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD006060-fig-0001"> <img data-id="CD006060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/image_n/nCD006060-AFig-FIG01.png" alt="QUOROM (quality of reporting of meta‐analyses) flow‐chart of study selection"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>QUOROM (quality of reporting of meta‐analyses) flow‐chart of study selection</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/full#CD006060-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/ppt/CDSR/CD006060/image_n/nCD006060-AFig-FIG01.png?filename=nCD006060-AFig-FIG01.ppt&amp;title=1&amp;caption=QUOROM%20%28quality%20of%20reporting%20of%20meta%E2%80%90analyses%29%20flow%E2%80%90chart%20of%20study%20selection&amp;citation=Richter B, Bandeira%E2%80%90Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, 4. Art. No.: CD006060. DOI: http://dx.doi.org/10.1002/14651858.CD006060.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/image_n/nCD006060-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006060-fig-00101"><img data-id="CD006060-fig-00101" src="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/image_n/nCD006060-CMP-001-01.png" alt="Comparison 1 Adverse events, Outcome 1 No. of patients experiencing oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Adverse events, Outcome 1 No. of patients experiencing oedema.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/references#CD006060-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/ppt/CDSR/CD006060/image_n/nCD006060-CMP-001-01.png?filename=nCD006060-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Adverse%20events%2C%20Outcome%201%20No.%20of%20patients%20experiencing%20oedema.&amp;citation=Richter B, Bandeira%E2%80%90Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, 4. Art. No.: CD006060. DOI: http://dx.doi.org/10.1002/14651858.CD006060.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006060.pub2/media/CDSR/CD006060/image_n/nCD006060-CMP-001-01.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006060-tbl-0001" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Adverse events</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 No. of patients experiencing oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11565</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.22 [1.96, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Adverse events</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006060.pub2/references#CD006060-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006060-note-1205">Español</a> </li> <li class="section-language"> <a class="" href="ja#CD006060-note-1201">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006060-note-1204">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581423095000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581423095000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717708000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717777000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717709000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717714000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006060\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006060\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006060\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006060\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581423095000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=y8F68iId&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD006060.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD006060.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006060.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583237608206" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">

<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583237608210" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006060&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD006060.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 